## ITEMS OF IMPORTANCE

All Providers Are Expected to Subscribe to WPS GHA Medicare eNews - Sign Up Today! ................................. 2

## CLAIM SUBMISSION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPTCs April 2017 Code Set Update (MM 9869)</td>
<td>3</td>
</tr>
<tr>
<td>Implementation of New Influenza Virus Vaccine Code (Revised MM 9876)</td>
<td>5</td>
</tr>
<tr>
<td>New CWF MSP Type for LMSAs and NFMSAs (Revised MM 9893)</td>
<td>8</td>
</tr>
<tr>
<td>New Waived Tests (Revised MM 9956)</td>
<td>11</td>
</tr>
<tr>
<td>Qualified Medicare Beneficiary Indicator in the Medicare Fee-For-Service Claims Processing System (Revised MM 9911)</td>
<td>16</td>
</tr>
<tr>
<td>Quarterly Update to the NCCI PTP Edits, Version 23.2, Effective July 1, 2017 (MM 10082)</td>
<td>19</td>
</tr>
<tr>
<td>Two New “K” Codes for Therapeutic Continuous Glucose Monitors (MM 10013)</td>
<td>21</td>
</tr>
<tr>
<td>Updated Editing of Professional Therapy Services (MM 9933)</td>
<td>23</td>
</tr>
</tbody>
</table>

## COVERAGE – GENERAL

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes to the Laboratory NCD Edit Software for July 2017 (MM 10036)</td>
<td>27</td>
</tr>
<tr>
<td>Gender Dysphoria and Gender Reassignment Surgery (MM 9981)</td>
<td>29</td>
</tr>
<tr>
<td>ICD-10 Coding Revisions to NCDs (MM 9861)</td>
<td>31</td>
</tr>
<tr>
<td>ICD-10 Coding Revisions to NCDs (MM 9982)</td>
<td>34</td>
</tr>
<tr>
<td>Screening for HBV Infection (MM 9859)</td>
<td>37</td>
</tr>
<tr>
<td>The Process of Prior Authorization (Revised MM 9940)</td>
<td>46</td>
</tr>
</tbody>
</table>

## COVERAGE – POLICIES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information on Website</td>
<td>49</td>
</tr>
<tr>
<td>New Policies</td>
<td>49</td>
</tr>
<tr>
<td>Retired Policies</td>
<td>50</td>
</tr>
<tr>
<td>Revised Policies</td>
<td>50</td>
</tr>
</tbody>
</table>

## GENERAL INFORMATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Physician Specialty Code for Advanced Heart Failure and Transplant Cardiology, Medical Toxicology, and Hematopoietic Cell Transplantation and Cellular Therapy (MM 9957)</td>
<td>68</td>
</tr>
</tbody>
</table>

## REIMBURSEMENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remittance Advice Remark Code (RARC), CARC, MREP and PC Print Update (MM 9878)</td>
<td>70</td>
</tr>
<tr>
<td>Updates to the “Medicare Claims Processing Manual,” Pub. 100-04, Chapters 12, 17 and 23 to Correct Remittance Advice Messages (MM 9906)</td>
<td>72</td>
</tr>
</tbody>
</table>

## PROVIDER EDUCATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education Schedule</td>
<td>74</td>
</tr>
<tr>
<td>Medicare Learning Network (MLN)</td>
<td>77</td>
</tr>
<tr>
<td>Quarterly Provider Update</td>
<td>78</td>
</tr>
</tbody>
</table>

## REMITTANCE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unsolicited/Voluntary Refunds</td>
<td>79</td>
</tr>
<tr>
<td>April 2017 Update of the ASC Payment System (MM 9998)</td>
<td>80</td>
</tr>
<tr>
<td>April Quarterly Update for 2017 DMEPOS Fee Schedule (MM 9988)</td>
<td>85</td>
</tr>
<tr>
<td>Clinical Laboratory Fee Schedule – Medicare Travel Allowance Fees for Collection of Specimens (MM 9960)</td>
<td>89</td>
</tr>
<tr>
<td>Episode Payment Model Operations (Rescinded MM 9916)</td>
<td>91</td>
</tr>
<tr>
<td>July 2017 Quarterly ASP Medicare Part B Drug Pricing Files and Revision to Prior Quarterly Pricing Files (MM 10016)</td>
<td>92</td>
</tr>
<tr>
<td>July Quarterly Update for 2017 DMEPOS Fee Schedule (MM 10071)</td>
<td>94</td>
</tr>
<tr>
<td>Payment for Moderate Sedation Services (MM 10001)</td>
<td>97</td>
</tr>
<tr>
<td>Payment for Moderate Sedation Services Furnished with Colorectal Cancer Screening Tests (MM 10075)</td>
<td>99</td>
</tr>
<tr>
<td>Quarterly Update to the MPFSDB - April CY 2017 Update (MM 9977)</td>
<td>101</td>
</tr>
</tbody>
</table>

This bulletin should be shared with all health care practitioners and managerial members of the provider staff. Bulletins are available at no cost from our website: [http://www.wpsgha.com](http://www.wpsgha.com)
Items of Importance

ALL PROVIDERS ARE EXPECTED TO SUBSCRIBE TO WPS GHA MEDICARE ENEWS - SIGN UP TODAY!

WPS GHA is pleased to offer the convenient services of our WPS GHA Medicare eNews to all providers in our jurisdiction. WPS GHA Medicare eNews is an electronic newsletter sent to you via email. When you subscribe, WPS GHA Medicare eNews will bring the latest Medicare news directly to your email box, free of charge! You may unsubscribe at any time, and, as with all aspects of the WPS GHA publications, we value your privacy and will never disclose, give, sell or transfer any personally identifiable information to third parties.

WPS GHA Medicare eNews announces the posting of the following:
- Time-sensitive national and local Medicare news
- Medicare program changes
- Policy updates, including new, retired, and revised policies
- Training events (including seminars, teleconferences, webinars, and on demand trainings!)
- Communiqué newsletters
- Specialty- and service-specific educational articles
- Much, much more!

It is important to note that the Centers for Medicare & Medicaid Services (CMS) requires Medicare contractors (including WPS GHA) to increase provider subscribership to their eNews every year. In addition, CMS has instructed that every Medicare provider (including physicians, nurses, and billing staff) should be subscribed to eNews. It is a common misconception that only one provider in an office can be subscribed to WPS GHA Medicare eNews; CMS and WPS GHA encourage and expect all Medicare providers to subscribe to eNews.

Sign up today! Visit our website at https://corp-ws.wpsic.com/apps/commercial/unauth/medicareListservUserWelcomeLoadAction.do to subscribe (it only takes a minute). And if you know a co-worker or another Medicare provider who isn't receiving WPS GHA Medicare eNews, let them know that they're missing out on a very informative educational resource and direct them to https://corp-ws.wpsic.com/apps/commercial/unauth/medicareListservUserWelcomeLoadAction.do to sign up as well!
Healthcare Provider Taxonomy Codes (HPTCs) April 2017 Code Set Update

Provider Types Affected

This MLN Matters® Article is intended for physicians, other providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs), including Home Health and Hospice MACs and Durable Medical Equipment MACs, for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9869 instructs MACs to obtain the most recent Healthcare Provider Taxonomy Code (HPTC) set and to update their internal HPTC tables and/or reference files.

Background

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) requires that covered entities use the standards adopted under this law for electronically transmitting certain health care transactions, including health care claims. The standards include implementation guides which dictate when and how data must be sent, including specifying the code sets which must be used. The institutional and professional claim electronic standard implementation guides (X12 837-I and 837-P) each require use of valid codes contained in the HPTC set when there is a need to report provider type or physician, practitioner, or supplier specialty for a claim.

The National Uniform Claim Committee (NUCC) maintains the HPTC set for standardized classification of health care providers, and updates it twice a year with changes effective April 1 and October 1. These changes include the addition of a new code and addition of definitions to existing codes.
You should note that:

1. Valid HPTCs are those that the NUCC has approved for current use.
2. Terminated codes are not approved for use after a specific date.
3. Newly approved codes are not approved for use prior to the effective date of the code set update in which each new code first appears.
4. Specialty and/or provider type codes issued by any entity other than the NUCC are not valid.

CR9869 implements the NUCC HPTC code set that is effective on April 1, 2017, and instructs MACs to obtain the most recent HPTC set and use it to update their internal HPTC tables and/or reference files. MACs will implement the April 2017 HPTC update as soon as they can after April 1, 2017, but not beyond July 3, 2017. The HPTC set is available for view or for download from the Washington Publishing Company (WPC) at http://www.wpc-edi.com/codes.

When reviewing the Health Care Provider Taxonomy code set online, you can identify revisions made since the last release by the color code:

- New items are green
- Modified items are orange
- Inactive items are red

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Implementation of New Influenza Virus Vaccine Code

Note: This article was revised on April 21, 2017, to reflect a revised CR9876 issued that day. In the article, the CR release date, transmittal number, and the Web address for accessing the CR are revised. All other information remains the same.

Provider Types Affected

This MLN Matters® Article is intended for physicians, other providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

What You Need to Know

Change Request (CR) 9876 provides instructions for payment and edits for the common working file (CWF) to include influenza virus vaccine code 90682 (Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use) for claims with dates of service on or after July 1, 2017. Make sure that your billing staffs are aware of these instructions.

Background

Effective for dates of service on and after July 1, 2017, influenza virus code 90682 will be payable by Medicare. Annual Part B deductible and coinsurance amounts do not apply to this code. MACs will:

- Effective for dates of service on or after August 1, 2017, MACs will pay for code 90682 using the Centers for Medicare & Medicaid Services (CMS) Seasonal
Influenza Vaccines Pricing at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/VaccinesPricing.html to determine the payment rate for influenza virus vaccine code 90682.

- Pay for vaccine code 90682 on institutional claims as follows:
  - Hospitals – Types of Bill (TOB) 12X and 13X, Skilled Nursing Facilities (SNFs) – TOB 22X and 23X, Home Health Agencies (HHAs) – TOB 34X, hospital-based Renal Dialysis Facilities (RDFs) – TOB 72X, and Critical Access Hospitals (CAHs) – TOB 85X, based on reasonable cost
  - Indian Health Service (IHS) Hospitals – TOB 12X, and 13X, IHS CAHs – TOB 85X, and hospices (81X and 82X) based on the lower of the actual charge or 95 percent of the Average Wholesale Price (AWP)
  - Comprehensive Outpatient Rehabilitation Facility (CORF) – TOB 75X, and independent RDFs – TOB 72X, based on the lower of actual charge or 95 percent of the AWP
- MACs will pay at discretion claims for code 90682 with dates of service July 1, 2017, through July 31, 2017.
- MACs will return to the provider (RTP) institutional claims if submitted with code 90682 for dates of service January 1, 2017, through June 30, 2017.
- MACs will deny Part B claims submitted with code 90682 for dates of service January 1, 2017, through June 30, 2017, using the following messages:
  - Claim Adjustment Reason Code: 181 – “Procedure code was invalid on the date of service.”
  - Remittance Advice Remark Code: N56 – “Procedure code billed is not correct/valid for the services billed or the date of service billed.”
  - Group Code: CO (Contractual Obligation)

In addition, effective for claims with dates of service on or after October 1, 2016, MACs will pay vaccines (Influenza, PPV, and HepB) to hospices based on the lower of the actual charge or 95% of AWP. Coinsurance and deductibles do not apply. Further, MACs will adjust previously processed hospice claims (TOB 81x or 82x) for these vaccines with dates of service on or after October 1, 2016.

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.
Document History

- February 3, 2017 - Initial article released.
- April 21, 2017 - The article was revised to reflect a revised CR9876 issued that day. In the article, the CR release date, transmittal number, and the Web address for accessing the CR are revised. All other information remains the same.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
New Common Working File (CWF) Medicare Secondary Payer (MSP) Type for Liability Medicare Set-Aside Arrangements (LMSAs) and No-Fault Medicare Set-Aside Arrangements (NFMSAs)

Note: This article was revised on May 10, 2017, due to the release of an updated Change Request (CR). The CR date, transmittal number and the link to the transmittal changed. All other information remains the same.

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

What You Need to Know

This article is based on CR 9893. To comply with the Government Accountability Office (GAO) final report entitled Medicare Secondary Payer (MSP): Additional Steps Are Needed to Improve Program Effectiveness for Non-Group Health Plans (GAO 12-333), the Centers for Medicare & Medicaid Services (CMS) will establish two (2) new set-aside processes: a Liability Insurance Medicare Set-Aside Arrangement (LMSA), and a No-Fault Insurance Medicare Set-Aside Arrangement (NFMSA). An LMSA or an NFMSA is an allocation of funds from a liability or an auto/no-fault related settlement, judgment, award, or other payment that is used to pay for an individual’s future medical and/or future prescription drug treatment expenses that would otherwise be reimbursable by Medicare.

Please be sure your billing staffs are aware of these changes.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Background

CMS will establish two (2) new set-aside processes: a Liability Medicare Set-aside Arrangement (LMSA), and a No-Fault Medicare Set-aside Arrangement (NFMSA).

CR 9893 addresses (1) the policies, procedures, and system updates required to create and utilize an LMSA and an NFMSA MSP record, similar to a Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) MSP record, and (2) instructs the MACs and shared systems when to deny payment for items or services that should be paid from an LMSA or an NFMSA fund.

Pursuant to 42 U.S.C. Sections 1395y(b)(2) and 1862(b)(2)(A)(ii) of the Social Security Act, Medicare is precluded from making payment when payment “has been made or can reasonably be expected to be made under a workers’ compensation plan, an automobile or liability insurance policy or plan (including a self-insured plan), or under no-fault insurance.” Medicare does not make claims payment for future medical expenses associated with a settlement, judgment, award, or other payment because payment “has been made” for such items or services through use of LMSA or NFMSA funds. However, Liability and No-Fault MSP claims that do not have a Medicare Set-Aside Arrangement (MSA) will continue to be processed under current MSP claims processing instructions.

Key Points of CR9893

Medicare will not pay for those services related to the diagnosis code (or related within the family of diagnosis codes) associated with the open LMSA or NFMSA MSP record when the claim’s date of service is on or after the MSP effective date and on or before the MSP termination date. Your MAC will deny such claims using Claim Adjustment Reason Code (CARC) 201 and Group Code “PR” will be used when denying claims based on the open LMSA or NFMSA MSP auxiliary record.

In addition to CARC 201 and Group Code PR, when denying a claim based upon the existence of an open LMSA or NFMSA MSP record, your MAC will include the following Remittance Advice Remark Codes (RARCs) as appropriate to the situation:

- N723—Patient must use Liability Set Aside (LSA) funds to pay for the medical service or item.
- N724—Patient must use No-Fault Set-Aside (NFSA) funds to pay for the medical service or item.

Where appropriate, MACs may override and make payment for claim lines or claims on which:

- Auto/no-fault insurance set-asides diagnosis codes do not apply, or
- Liability insurance set-asides diagnosis codes do not apply, or are not related, or
• When the LMSA and NFMSA benefits are exhausted/terminated per CARC or RARC and payment information found on the incoming claim as cited in CR9009.

On institutional claims, if the MAC is attempting to allow payment on the claim, the MAC will include an “N” on the ‘001’ Total revenue charge line of the claim.

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

Document History

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 10, 2017</td>
<td>The article was revised due to the release of an updated Change Request (CR). The CR date, transmittal number and the link to the transmittal changed.</td>
</tr>
<tr>
<td>February 17, 2017</td>
<td>Initial article released</td>
</tr>
</tbody>
</table>

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
New Waived Tests

Note: This article was revised on April 3, 2017, to reflect the revised CR9956 issued on March 30, 2017. In the article, the CR release date, transmittal number, and the Web address for CR9956 are revised. All other information remains the same. The CR was revised to correct CPT drug test code from 80305 to 80305QW in the attachment to CR9956.

Provider Types Affected

This MLN Matters® Article is intended for clinical diagnostic laboratories submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9956 informs MACs of new Clinical Laboratory Improvement Amendments of 1988 (CLIA) waived tests approved by the Food and Drug Administration (FDA). Since these tests are marketed immediately after approval, the Centers for Medicare & Medicaid Services (CMS) must notify MACs of the new tests so that they can accurately process claims. Make sure that your billing staffs are aware of these CLIA-related changes.

Background

The CLIA regulations require a facility to be appropriately certified for each test performed. To ensure that Medicare & Medicaid only pay for laboratory tests categorized as waived complexity under CLIA in facilities with CLIA certificate of waiver, laboratory claims are currently edited at the CLIA certificate level.
Listed below are the latest tests approved by the FDA as waived tests under CLIA. The Current Procedural Terminology (CPT) codes for the following new tests must have the modifier QW to be recognized as a waived test. However, the tests mentioned on the first page of the list attached to CR9956 (CPT codes: 81002, 81025, 82270, 82272, 82962, 83026, 84830, 85013, and 85651) do not require a QW modifier to be recognized as a waived test.

The CPT code, effective date and description for the latest tests approved by the FDA as waived tests under CLIA are the following:

- **G0477QW** [from July 7, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], July 7, 2016, TransMed Company, CLIA Screen In-Vitro Multi-Drug Urine Test Dip Card
- **G0477QW** [from July 7, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], July 7, 2016, TransMed Company, CLIA Screen In-Vitro Multi-Drug Urine Test Dip Cup
- **G0477QW** [from August 11, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], August 11, 2016, Nobel Medical Inc., AEON Multi-Drug Urine Test Cup
- **G0477QW** [from August 11, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], Nobel Medical Inc., August 11, 2016, AEON Multi-Drug Urine Test Dip Card
- **G0477QW** [from August 11, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], August 11, 2016, Nobel Medical Inc., INSTA-SCREEN Multi-Drug Urine Test Dip Card
- 82274QW, G0328QW, September 6, 2016, ProAdvantage Immunochemical Fecal Occult Blood Test
- 87880QW, September 16, 2016, Cardinal Health Strep A Cassette Rapid Test
- **G0477QW** [from September 16, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], September 16, 2016, Premier Biotech, Inc., MDETOX Multi-Drug Urine Test Cup
• G0477QW [from September 16, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], September 16, 2016, Premier Biotech, Inc., MDETOX Multi-Drug Urine Test Dip Card

• 81003QW, October 7, 2016. Moore Medical LLC mooremedical U120 Urine Analyzer

• 87633QW, October 7, 2016, BioFire Diagnostics, FilmArray 2.0 EZ Configuration Instrument (Viral and Bacterial Nucleic Acids) {Nasopharyngeal Swabs}

• 87804QW, October 7, 2016, BioSign Flu A+B {Nasal and nasopharyngeal swabs}

• G0477QW [from October 24, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], October 24, 2016, Identify BioSciences Inc., Identifi Multi-Panel Drug Test Cups (Urine) {Cup Format}

• G0477QW [from October 25, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], October 25, 2016, UCP Biosciences, Inc. U-Card Drug Test Screen (Urine) {Card Format}

• G0477QW [from October 25, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], October 25, 2016, UCP Biosciences, Inc. U-Cup Drug Test Screen (Urine) {Cup Format}

• G0477QW [from October 26, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], Intrinsic Interventions Inc., Vista Flow

• 87804QW, November 15, 2016, LifeSign LLC, Status Flu A+B

• 87804QW, November 21, 2016, Sekisui Diagnostics LLC, OSOM Ultra Flu A&B Test

• G0477QW [from November 23, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], November 23, 2016, Medical Distribution Group Inc., Identify Diagnostics Drug Test Cards (UPC Biosciences, Inc.)

• G0477QW [from November 23, 2016, to December 31, 2016], 80305QW [on and after January 1, 2017], November 23, 2016, Medical Distribution Group Inc., Identify Diagnostics Drug Test Cups (UPC Biosciences, Inc.)

• 87804QW, November 25, 2016, OraSure QuickFlu Rapid A+B Test {Nasal and Nasopharyngeal Swabs}
The HCPCS code G0477 [Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures, (eg, immunoassay) capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service] was discontinued on 12/31/2016. The new HCPCS code 80305 [Drug test(s), presumptive, any number of drug classes, any number of devices or procedures (eg, immunoassay); capable of being read by direct optical observation only (eg, dipsticks, cups, cards, cartridges) includes sample validation when performed, per date of service] was effective 1/1/2017. HCPCS code 80305QW describes the waived testing previously assigned the code G0477QW. All tests in the attachment that previously had HCPCS G0477QW are now assigned 80305QW.

The new waived complexity code 87633QW [Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), multiplex reverse transcription and amplified probe technique, multiple types or subtypes, 12-25 targets] was assigned for the testing performed by BioFire Diagnostics, FilmArray 2.0 EZ Configuration Instrument (Viral and Bacterial Nucleic Acids){Nasopharyngeal Swabs}.

The attachment to CR9956 has been re-organized. HCPCS codes with more than 20 test systems listed in previous transmittal attachments will now not mention the specific waived complexity test system. Instead, there will be a generic test system name and a statement to refer to the FDA waived analytes internet site (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/analyteswaived.cfm) for the specific test system name. The HCPCS codes mentioned on the attachment that will now only be mentioned in a generic manner are G0477QW (80305QW effective 1/1/2017), 81003QW, 82274QW, G0328QW, 86308QW, 86318QW, and 87880QW. For these codes, future New Waived Test transmittals will only mention the specific name of the latest FDA test system in the transmittal and not be included in the attachment.

MACs will not search their files to either retract payment or retroactively pay claims based on these changes. However, MACs should adjust claims that you bring to their attention.

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.
Document History

January 20, 2017 – Initial article release.

April 3, 2017 – The article was revised to reflect the revised CR9956 issued on March 30, 2017. In the article, the CR release date, transmittal number, and the Web address for CR9956 are revised. All other information remains the same. The CR was revised to correct CPT drug test code from 80305 to 80305QW in the attachment to CR9956.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.
Qualified Medicare Beneficiary Indicator in the Medicare Fee-For-Service Claims Processing System

Note: The article was revised on May 1, 2017, to reflect a revised CR9911 issued on April 28, 2017. In the article, the CR release date, transmittal number, and the Web address of CR9911 are revised. All other information remains the same.

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs), including Home Health & Hospice MACs and Durable Medical Equipment MACs, for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9911 modifies the Medicare claims processing systems to help providers more readily identify the Qualified Medicare Beneficiary (QMB) status of each patient and to support providers’ ability to follow QMB billing requirements. Beneficiaries enrolled in the QMB program are not liable to pay Medicare cost-sharing for all Medicare A/B claims. CR 9911 adds an indicator of QMB status to Medicare’s claims processing systems. This system enhancement will trigger notifications to providers (through the Provider Remittance Advice) and to beneficiaries (through the Medicare Summary Notice) to reflect that the beneficiary is enrolled in the QMB program and has no Medicare cost-sharing liability. Make sure that your billing staffs are aware of these changes.
**Background**

QMB is a Medicaid program that assists low-income beneficiaries with Medicare premiums and cost-sharing. In 2015, 7.2 million persons (more than one out of every ten Medicare beneficiaries) were enrolled in the QMB program.

Under federal law, Medicare providers may not bill individuals enrolled in the QMB program for Medicare deductibles, coinsurance, or copayments, under any circumstances. (See Sections 1902(n)(3)(B); 1902(n)(3)(C); 1905(p)(3); 1866(a)(1)(A); 1848(g)(3)(A) of the Social Security Act.) State Medicaid programs may pay providers for Medicare deductibles, coinsurance, and copayments. However, as permitted by Federal law, states can limit provider reimbursement for Medicare cost-sharing under certain circumstances. Nonetheless, Medicare providers must accept the Medicare payment and Medicaid payment (if any, and including any permissible Medicaid cost sharing from the beneficiary) as payment in full for services rendered to an individual enrolled in the QMB program.

CR 9911 aims to support Medicare providers’ ability to meet these requirements by modifying the Medicare claims processing system to clearly identify the QMB status of all Medicare patients. Currently, neither the Medicare eligibility systems (the HIPAA Eligibility Transaction System (HETS)), nor the claims processing systems (the FFS Shared Systems), notify providers about their patient’s QMB status and lack of Medicare cost-sharing liability. Similarly, Medicare Summary Notices (MSNs) do not inform those enrolled in the QMB program that they do not owe Medicare cost-sharing for covered medical items and services.

CR 9911 includes modifications to the FFS claims processing systems and the “Medicare Claims Processing Manual” to generate notifications to Medicare providers and beneficiaries regarding beneficiary QMB status and lack of liability for cost-sharing.

With the implementation of CR 9911, Medicare’s Common Working File (CWF) will obtain QMB indicators so the claims processing systems will have access to this information.

- CWF will provide the claims processing systems the QMB indicators if the dates of service coincide with a QMB coverage period (one of the occurrences) for the following claim types: Part B professional claims; Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) claims; and outpatient institutional Types of Bill (TOB) 012x, 013x, 014x, 022x, 023x, 034x, 071x, 072x, 074x, 075x, 076x, 077x, and 085x); home health claims (TOB 032x) only if the revenue code for the line item is 0274, 029x, or 060x; and Skilled Nursing Facility (SNF) claims (based on occurrence code 50 date for revenue code 0022 lines on TOBs 018x and 021x).

- CWF will provide the claims processing systems the QMB indicator if the "through date" falls within a QMB coverage period (one of the occurrences) for inpatient hospital claims (TOB 011x) and religious non-medical health care institution claims (TOB 041x).
The QMB indicators will initiate new messages on the Remittance Advice that reflect the beneficiary’s QMB status and lack of liability for Medicare cost-sharing with three new Remittance Advice Remark Codes (RARC) that are specific to those enrolled in QMB. As appropriate, one or more of the following new codes will be returned:

- **N781** – No deductible may be collected as patient is a Medicaid/Qualified Medicare Beneficiary. Review your records for any wrongfully collected coinsurance, deductible or co-payments.
- **N782** – No coinsurance may be collected as patient is a Medicaid/Qualified Medicare Beneficiary. Review your records for any wrongfully collected coinsurance, deductible or co-payments.
- **N783** – No co-payment may be collected as patient is a Medicaid/Qualified Medicare Beneficiary. Review your records for any wrongfully collected coinsurance, deductible or co-payments.

In addition, the MACs will include a Claim Adjustment Reason Code of 209 (“Per regulatory or other agreement. The provider cannot collect this amount from the patient. However, this amount may be billed to subsequent payer. Refund to patient if collected. (Use only with Group code OA (Other Adjustment)).

Finally, CR 9911 will modify the MSN to inform beneficiaries if they are enrolled in QMB and cannot be billed for Medicare cost-sharing for covered items and services.

### Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

### Document History

- **February 3, 2017** - Initial article released.
- **May 1, 2017** - The article was revised to reflect a revised CR9911 issued on April 28, 2017. In the article, the CR release date, transmittal number, and the Web address of CR9911 are revised. All other information remains the same.

### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Quarterly Update to the National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) Edits, Version 23.2, Effective July 1, 2017

MLN Matters Number: MM10082  Related Change Request (CR) Number: CR10082
Related CR Release Date: April 14, 2017  Effective Date: July 1, 2017
Related CR Transmittal Number: R3748CP  Implementation Date: July 3, 2017

PROVIDER TYPES AFFECTED

This MLN Matters® Article is intended for physicians, other providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

Change Request (CR) 10082 informs Medicare Administrative Contractors (MACs) about the update to the National Correct Coding Initiative (NCCI) procedure to procedure edits (PTP). This notice applies to Chapter 23, Section 20.9 of the Medicare Claims Processing Manual. Make sure your billing staffs are aware of these changes.

BACKGROUND

The Centers for Medicare & Medicaid Services (CMS) developed the NCCI to promote national correct coding methodologies and to control improper coding that leads to inappropriate payment in Part B claims.

Version 23.2 will include all previous versions and updates from January 1, 1996, to the present. In the past, CCI was organized in two tables: Column 1/Column 2 Correct Coding Edits and Mutually Exclusive Code (MEC) Edits. In order to simplify the use of NCCI edit files (two tables), on April 1, 2012, CMS consolidated these two edit files into the Column One/Column Two Correct Coding edit file. Separate consolidations have occurred for the two practitioner NCCI edit files and the two NCCI edit files used for the Outpatient Code Editor (OCE). It will only be necessary to search the Column One/Column Two Correct Coding edit file for active or previously deleted edits. CMS no longer publishes a Mutually Exclusive edit file on its website for either practitioner or outpatient hospital services, since all active and deleted edits will appear in the single Column One/Column Two Correct Coding edit file on each website. The edits previously contained in the Mutually Exclusive edit file are NOT being deleted but
are being moved to the Column One/Column Two Correct Coding edit file. Refer to the CMS NCCI webpage for additional information at http://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd/index.html.

The coding policies developed are based on coding conventions defined in the American Medical Association’s Current Procedural Terminology manual, national and local policies and edits, coding guidelines developed by national societies, analysis of standard medical and surgical practice, and review of current coding practice.

ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 14, 2017</td>
<td>Initial Article Released</td>
</tr>
</tbody>
</table>

Disclaimer This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Two New “K” Codes for Therapeutic Continuous Glucose Monitors

MLN Matters Number: MM10013 Related Change Request (CR) Number: 10013
Related CR Release Date: April 28, 2017 Effective Date: July 1, 2017
Related CR Transmittal Number: R3751CP Implementation Date: July 3, 2017

PROVIDER TYPE AFFECTED

This MLN Matters Article is intended for providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

WHAT YOU NEED TO KNOW

Change Request (CR) 10013 provides the two codes for therapeutic Continuous Glucose Monitors (CGM) that will be added to the Healthcare Common Procedure Coding System (HCPCS) code set, effective July 1, 2017. The addition of these codes (K0553 and K0554) will facilitate Durable Medical Equipment (DME) MAC claims processing for therapeutic CGMs. Make sure that your billing staffs are aware of these two new codes.

BACKGROUND

On January 12, 2017, the Centers for Medicare & Medicaid Services (CMS) issued a Ruling (CMS-1682-R), concluding that certain CGM, referred to as therapeutic CGMs, are considered durable medical equipment (DME).

Continuous glucose monitoring systems are considered therapeutic CGMs (and therefore DME), if the equipment:

• Is approved by the Food and Drug Administration for use in place of a blood glucose monitor for making diabetes treatment decisions (for example, changes in diet and insulin dosage)
• Is generally not useful to the individual in the absence of an illness or injury
• Is appropriate for use in the home
• Includes a durable component (a component that CMS determines can withstand repeated use and has an expected lifetime of at least 3 years) that is capable of displaying the trending of the continuous glucose measurements
To facilitate implementation of this Ruling, the following two codes will be added to the HCPCS code set effective July 1, 2017:

1. K0553 Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 unit of service = 1 month’s supply
2. K0554 Receiver (Monitor), dedicated, for use with therapeutic continuous glucose monitor system.

The billing jurisdiction for both of these codes will be the DME MAC.

ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 1, 2017</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Updated Editing of Professional Therapy Services

Provider Types Affected

This MLN Matters® is intended for physicians, therapists, and other practitioners who submit professional claims to Medicare Administrative Contractors (MACs) for therapy services provided to Medicare beneficiaries.

Provider Action Needed

Change request (CR) 9933 instructs the MACs to apply certain coding edits to the new Current Procedural Terminology (CPT) codes that are used to report physical therapy (PT) and occupational therapy (OT) evaluations and re-evaluations, effective January 1, 2017. Make sure your billing staffs are aware of these coding changes.

Background

Original Medicare claims processing systems contain edits to ensure claims for the evaluative procedures furnished by rehabilitative therapy clinicians – including physical therapists, occupational therapists and speech-language pathologists – are coded correctly. These edits ensure that when the codes for evaluative services are submitted, the therapy modifier (GP, GO, or GN) that reports the type of therapy plan of care is consistent with the discipline described by the evaluation or re-evaluation code. The edits also ensure that Functional Reporting occurs, which is to say that functional G-codes, along with severity modifiers, always accompany codes for therapy evaluative services. These edits were applied to institutional claims in CR9698. A related article is available at https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-
MLN/MLNMattersArticles/Downloads/MM9698.pdf. CR9933 applies these edits to professional claims.

For Calendar Year (CY) 2017, eight new CPT codes (97161-97168) were created to replace existing codes (97001-97004) to report PT and OT evaluations and reevaluations. The new CPT code descriptors include specific components that are required for reporting as well as the typical face-to-face times. In CR9782, the Centers for Medicare & Medicaid Services (CMS) described the new PT and OT code sets, each comprised of three new codes for evaluation – stratified by low, moderate, and high complexity – and one code for reevaluation. CR9782 designated all eight new codes as “always therapy” (always require a therapy modifier) and added them to the 2017 therapy code list located at http://www.cms.gov/Medicare/Billing/TherapyServices/index.html. For a complete listing of the new codes, their CPT long descriptors, and related policies, see the related article for CR9782 at https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM9782.pdf.

CR9933 applies the coding requirements for certain evaluative procedures that are currently outlined in the “Medicare Claims Processing Manual (MCPM),” Chapter 5, to the new codes for PT and OT evaluative procedures. These new PT and OT codes 97161 – 97168 were added to the applicable code lists in MCPM, Chapter 5, by CR9698.

Key Points

CR9933 implements the following payment policies related to professional claims for therapy services for the new CPT codes for PT and OT evaluative procedures – claims without the required information will be returned/rejected:

Therapy modifiers

The new PT and OT codes are added to the current list of evaluative procedures that require a specific therapy modifier to identify the plan of care under which the services are delivered to be on the claim for therapy services. Therapy modifiers GP, GO, or GN are required to report the type of therapy plan of care – PT, OT, or speech-language pathology, respectively. This payment policy requires that each new PT evaluative procedure code – 97161, 97162, 97163 or 97164 – to be accompanied by the GP modifier; and, (b) each new code for an OT evaluative procedure – 97165, 97166, 97167 or 97168 – be reported with the GO modifier.

Functional Reporting

In addition to other Functional Reporting requirements, Medicare payment policy requires Functional Reporting, using G-codes and severity modifiers, when an evaluative procedure is furnished and billed. This notification adds the eight new codes for PT and OT evaluations and re-evaluations – 97161, 97162, 97163, 97164, 97165, 97166, 97167, and 97168 – to the procedure code list of evaluative procedures that necessitate Functional
Reporting. A severity modifier (CH – CN) is required to accompany each functional G-code (G8978-G8999, G9158-9176, and G9186) on the same line of service.

For each evaluative procedure code, Functional Reporting requires either two or three functional G-codes and related severity modifiers be on the same claim. Two G-codes are typically reported on specified claims throughout the therapy episode. However, when an evaluative service is furnished that represents a one-time therapy visit, the therapy clinician reports all three G-codes in the functional limitation set – G-codes for Current Status, Goal Status and Discharge Status.

CMS coding requirements for Functional Reporting applied through CR9933 ensure that at least two G-codes in a functional set and their corresponding severity modifiers are present on the same claim with any one of the codes on this evaluative procedure code list. The required reporting of G-codes includes: (a) G-codes for Current Status and Goal Status; or, (b) G-codes for Discharge Status and Goal Status.


Claim Coding Requirements:

Therapy Modifiers. Your MAC will return/reject professional claims when:

- Reporting codes 97161, 97162, 97163, or 97164 without the GP modifier.
- Reporting codes 97165, 97166, 97167, or 97168 without the GO modifier.
- Reporting an “always therapy” code without a therapy modifier

For these returned/rejected claims, your MAC will supply the following messages:

- Group code CO
- CARC – 4: The procedure code is inconsistent with the modifier used or a required modifier is missing.

Functional Reporting. Your MAC will return/reject claims when:

- The professional claims you submit for the new therapy evaluative procedures, codes 97161- 97168, without including one of the following pairs of G-codes/severity modifiers required for Functional Reporting: (a) A Current Status G-code/severity modifier paired with a Goal Status G-code/severity modifier; or, (b) A Goal Status G-code/severity modifier paired with a Discharge Status G-code/severity modifier.

Your MAC will provide the following remittance messages when returning such submissions:

- Group code of CO (contractual obligation)
- Claim Adjustment Reason Code (CARC) – 16: Claim/service lacks information or has submission/billing error(s) which is needed for adjudication.
- Remittance Advice Remarks Code (RARC) – N572: This procedure is not payable unless non-payable reporting codes and appropriate modifiers are submitted.

**Additional Information**


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Changes to the Laboratory National Coverage Determination (NCD) Edit Software for July 2017

MLN Matters Number: MM10036
Related Change Request (CR) Number: CR10036
Related CR Release Date: March 17, 2017
Effective Date: October 1, 2016
Related CR Transmittal Number: R3738CP
Implementation Date: July 3, 2017

PROVIDER TYPE AFFECTED

This MLN Matters Article is intended for physicians, providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

WHAT YOU NEED TO KNOW

This article is based on Change Request (CR) 10036 which announces the changes that will be included in the July 2017 quarterly release of the edit module for clinical diagnostic laboratory services. This is a Recurring Update Notification that applies to \textit{Chapter 16}, Section 120.2, of the "Medicare Claims Processing Manual." Make sure your billing staffs are aware of these changes.

BACKGROUND

The national coverage determinations (NCDs) for clinical diagnostic laboratory services were developed by the laboratory negotiated rulemaking committee and the final rule was published on November 23, 2001. Nationally uniform software was developed and incorporated in the Medicare shared systems so that laboratory claims subject to one of the 23 NCDs ("Medicare National Coverage Manual", \textit{Sections 190.12 - 190.34}) were processed uniformly throughout the nation effective April 1, 2003.

In accordance with \textit{Chapter 16}, S120.2, Publication 100-04, the laboratory edit module is updated quarterly as necessary to reflect ministerial coding updates and substantive changes to the NCDs developed through the NCD process. The changes are a result of coding analysis decisions developed under the procedures for maintenance of codes in the negotiated NCDs and biannual updates of the ICD-10-CM codes.
CR10036 communicates requirements to shared system maintainers (SSMs) and contractors notifying them of changes to the laboratory edit module to update it for changes in laboratory NCD code lists for July 2017. These changes become effective for services furnished on or after October 1, 2016, and are as follows:

- ICD-10-CM code R73.03 will be added to the list of ICD-10-CM codes that are covered by Medicare for the Glycated Hemoglobin/Glycated Protein (190.21) NCD.

- ICD-10-CM code R73.03 will be removed from the list of ICD-10-CM codes that are covered by Medicare for the Hepatitis Panel/Acute Hepatitis Panel (190.33) NCD.

### ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

### DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 20, 2017</td>
<td>Initial article released</td>
</tr>
</tbody>
</table>

**Disclaimer** This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Gender Dysphoria and Gender Reassignment Surgery

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

What You Need to Know

This article is based on Change Request (CR) 9981, which informs MACs that coverage determinations for gender reassignment surgery will continue to be made by the local MACs on a case-by-case basis. Make sure that your billing staffs are aware of these changes.

Background

On August 30, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a final decision memorandum (DM) on gender reassignment surgery for gender dysphoria. Importantly, the DM did not create or change existing policy – CMS did not issue a national coverage determination (NCD).

The purpose of this CR is to include an explanatory paragraph about gender reassignment surgery in the Medicare NCD Manual at Chapter 1, Part 2, Section 140.9. This is in response to public inquiries to have information about gender reassignment surgery among Medicare coverage information.

Policy: Effective for claims with dates of service on or after August 30, 2016, coverage determinations for gender reassignment surgery, under section 1862(a)(1)(A) of the Social Security Act and any other relevant statutory requirements, will continue to be made by the local Medicare Administrative Contractors (MACs) on a case-by-case basis.
Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/index.html on the CMS website under - How Does It Work.

Document History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 6, 2017</td>
<td>Article released</td>
</tr>
</tbody>
</table>
ICD-10 Coding Revisions to National Coverage Determination (NCDs)

Provider Types Affected

This MLN Matters® Article is intended for physicians and other providers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9861 is the 10th maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CRs, specifically CR7818, CR8109, CR8197, CR8691, CR9087, CR9252, CR9540, CR9631, and CR 9751; while others are the result of revisions required to other NCD-related CRs released separately. MLN Matters® Articles MM7818, MM8109, MM8197, MM8691, MM9087, MM9252, MM9540, MM9631, MM9751 contain information pertaining to these CR’s.

Background

The translations from ICD-9 to ICD-10 are not consistent 1-1 matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings (GEMS) mapping guide or other mapping guides appropriate when reviewed against individual NCD policies. In addition, for those policies that expressly allow MAC discretion, there may be changes to those NCDs based on current review of those NCDs against ICD-10 coding. There may be
certain ICD-9 codes that were once considered appropriate prior to ICD-10 implementation that are no longer considered acceptable, as of October 1, 2015.

No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases as needed.

CR9861 makes adjustments to the following 16 NCDs:

- NCD 40.1 - Diabetes Outpatient Self-Management Training
- NCD 40.7 - Outpatient Intravenous Insulin Treatment
- NCD 80.2 - Photodynamic Therapy (also NCD 80.2.1, 80.3, 80.3.1)
- NCD 80.11 - Vitrectomy
- NCD 100.1 - Bariatric Surgery
- NCD 110.4 – Extracorporeal Photopheresis
- NCD 110.18 - Aprepitant
- NCD 110.23 - Stem Cell Transplantation
- NCD 180.1 - Medical Nutrition Therapy
- NCD 190.1 – Histocompatibility Testing
- NCD 210.3 - Colorectal Cancer Screening
- NCD 220.4 - Mammograms
- NCD 220.6.17 - Positron Emission Tomography (PET) for Solid Tumors
- NCD 260.3.1 - Islet Cell Transplants
- NCD 260.5 - Intestinal and Multi-Visceral Transplants
- NCD 270.6 - Infrared Therapy Devices


You should remember that coding and payment areas of the Medicare Program are separate and distinct from coverage policy/criteria. Revisions to codes within an NCD are carefully and thoroughly reviewed and vetted by the Centers for Medicare & Medicaid Services and are not intended to change the original intent of the NCD. The exception to this is when coding revisions are released as official implementation of new or reconsidered NCD policy following a formal national coverage analysis.

Your MACs will use default Council for Affordable Quality Healthcare (CAQH) Committee on Operating Rules for Information Exchange (CORE) messages where appropriate: Remittance Advice Remark Code (RARC) N386 with Claim Adjustment
Reason Code (CARC) 50, 96, and/or 119, with Group Code PR (Patient Responsibility) or Group Code CO (Contractual Obligation), as appropriate.

Your MAC will not search their files to adjust previously processed claims but will adjust any claims that you bring to their attention if found appropriate to do so.

**Additional Information**


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services

MLN Matters® Number: MM9982
Related Change Request (CR) #: CR 9982
Related CR Release Date: February 17, 2017
Effective Date: July 1, 2017 (Unless otherwise noted in individual NCDs)
Related CR Transmittal #: R1798OTN
Implementation Date: March 20, 2017, for MAC edits and July 3, 2017, for Shared Systems

ICD-10 Coding Revisions to National Coverage Determinations (NCDs)

Provider Types Affected

This MLN Matters® Article is intended for physicians and other providers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

What You Need to Know

Change Request (CR) 9982 is the 11th maintenance update of ICD-10 conversions and other coding updates specific to national coverage determinations (NCDs). The majority of the NCDs included are a result of feedback received from previous ICD-10 NCD CRs, specifically CR7818, CR8109, CR8197, CR8691, CR9087, CR9252, CR9540, CR9631, CR9751, and CR9861; while others are the result of revisions required to other NCD-related CRs released separately. MLN Matters® Articles MM7818, MM8109, MM8197, MM8691, MM9087, MM9252, MM9540, MM9631, MM9751, and MM9861 contain information pertaining to these CRs.

Background

The translations from ICD-9 to ICD-10 are not consistent 1-1 matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings (GEMS) mapping guide or other mapping guides appropriate when reviewed against individual NCD policies. In addition, for those policies that expressly allow MAC discretion, there may be changes to those NCDs based on current review of those NCDs against ICD-10 coding. There may be
certain ICD-9 codes that were once considered appropriate prior to ICD-10 implementation that are no longer considered acceptable, as of October 1, 2015.

No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process. Edits to ICD-10 and other coding updates specific to NCDs will be included in subsequent, quarterly releases as needed.

CR9982 makes coding and clarifying adjustments to the following NCDs:

- NCD20.31 - Intensive Cardiac Rehabilitation (ICR)
- NCD20.31.1 - ICR Pritkin Program
- NCD20.31.2 - ICR Ornish Program
- NCD20.31.3 - ICR Benson-Henry Program
- NCD20.34 - Left Atrial Appendage Closure
- NCD190.3 - Cytogenetic Studies
- NCD260.3.1 - Islet Cell Transplants in Clinical Trials
- NCD270.1 - Electrical Stimulation & Electromagnetic Therapy for Treatment of Wounds
- NCD220.4 – Mammograms


Please remember that coding and payment areas of the Medicare Program are separate and distinct from coverage policy/criteria. Revisions to codes within an NCD are carefully and thoroughly reviewed and vetted by the Centers for Medicare & Medicaid Services (CMS) and are not intended to change the original intent of the NCD. The exception to this is when coding revisions are released as official implementation of new or reconsidered NCD policy following a formal national coverage analysis.

Your MACs will use default Council for Affordable Quality Healthcare (CAQH) Committee on Operating Rules for Information Exchange (CORE) messages where appropriate. MACs will complete all tasks that involve updates to local system edits/tables associated with the attached NCDs in this CR.

MACs will use default CAQH CORE messages where appropriate:


When denying claims associated with the attached NCDs, except where otherwise indicated, A/B MACs will use:
• Group Code PR (Patient Responsibility) assigning financial responsibility to the beneficiary (if a claim is received with occurrence code 32, or with occurrence code 32 and a GA modifier, indicating a signed ABN is on file).


Your MAC will not search their files to adjust previously processed claims but will adjust any claims that you bring to their attention if appropriate to do so.

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Screening for Hepatitis B Virus (HBV) Infection

Provider Types Affected

This MLN Matters® Article is intended for physicians and other providers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9859 provides that the Centers for Medicare & Medicaid Services (CMS) has determined that, effective September 28, 2016, Medicare will cover screening for Hepatitis B Virus (HBV) infection when performed with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA-approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations. Medicare coinsurance and the Part B deductible are waived for this additional preventive service. You should ensure that your billing staffs are aware of this coverage change.

Background

Pursuant to Section 1861(ddd) of the Social Security Act (the Act), CMS may add coverage of “additional preventive services” through the National Coverage Determination (NCD) process. The preventive services must meet all of the following criteria:

1. Reasonable and necessary for the prevention or early detection of illness or disability.
2. Recommended with a grade of A or B by the United States Preventive Services Task Force (USPSTF).
3. Appropriate for individuals entitled to benefits under Part A or enrolled under Part B.
The USPSTF has updated its recommendations for HBV screening, and CMS has reviewed these recommendations and supporting evidence; and has determined that the evidence is adequate to conclude that screening for HBV infection is reasonable and necessary for individuals entitled to benefits under Part A or enrolled under Part B, as described below.

Effective for services performed on or after September 28, 2016, Medicare will cover screening for HBV infection, when ordered by the beneficiary's primary care physician or practitioner within the context of a primary care setting, and performed by an eligible Medicare provider for these services, within the context of a primary care setting with the appropriate U.S. Food and Drug Administration (FDA) approved/cleared laboratory tests, used consistent with FDA-approved labeling and in compliance with the Clinical Laboratory Improvement Act (CLIA) regulations, for beneficiaries who meet either of the following conditions:

1. Asymptomatic, non-pregnant adolescents and adults at high risk for HBV infection. “High risk” is defined as persons born in countries and regions with a high prevalence of HBV infection (that is, ≥ 2%), US-born persons not vaccinated as infants whose parents were born in regions with a very high prevalence of HBV infection (≥ 8%), HIV positive persons, men who have sex with men, injection drug users, household contacts or sexual partners of persons with HBV infection. In addition, CMS has determined that repeated screening would be appropriate annually for beneficiaries with continued high risk persons. Testing is covered annually only for persons who have continued high risk (men who have sex with men, injection drug users, household contacts or sexual partners of persons with HBV infection) who have not received hepatitis B vaccination.

2. A screening test at the first prenatal visit is covered for pregnant women and then rescreening at time of delivery for those with new or continuing risk factors. In addition, CMS has determined that screening during the first prenatal visit would be appropriate for each pregnancy, regardless of previous hepatitis B vaccination or previous negative hepatitis B surface antigen (HBsAg) test results.

For the purposes of CR9859:

- The determination of ‘high risk for HBV” is identified by the primary care physician or practitioner who assesses the patient's history, which is part of any complete medical history, typically part of an annual wellness visit and considered in the development of a comprehensive prevention plan. The medical record should be a reflection of the service provided.

- A primary care setting is defined by the provision of integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. Emergency departments, inpatient hospital settings, ambulatory surgical centers, skilled nursing facilities, inpatient rehabilitation facilities, clinics providing a limited focus of health care services, and hospice are examples of settings not considered primary care settings under this definition.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Key Points of CR9859

Applicable Healthcare Common Procedure Coding System (HCPCS) Code
Effective for claims with dates of service on or after September 28, 2016, the claims processing instructions for payment of screening for hepatitis B virus will apply to the following HCPCS and CPT codes:

- HBV screening for asymptomatic, non-pregnant adolescents and adults at high risk - code G0499
- HBV screening for pregnant women - CPT codes 86704, 86706, 87340, and 87341

Types of Bills (TOB) for Institutional Claims
Effective for claims with dates of service on or after September 28, 2016, you should use the following TOBs when submitting claims with G0499, 87340, 87341, 86704, or 86706 for HBV screening:

- Outpatient hospitals - TOB 13X (payment based on Outpatient Prospective Payment System)
- Non-patient laboratory specimen - TOB 14X (payment based on laboratory fee schedule)
- Critical Access Hospitals (CAHs) - TOB 85X, (payment based on reasonable cost when the revenue code is not 096X, 097X, and 098X)
- End Stage Renal Disease (ESRD) - TOB 72X (payment based on ESRD Prospective Payment System when submitting code G0499 with diagnosis code N18.6. HBV is not separately payable for ESRD TOB 72X.)

Professional Billing Requirements
For claims with dates of service on or after September 28, 2016, CMS will allow coverage for HBV screening only when services are submitted by the following provider specialties found on the provider’s enrollment record:

- 01 - General Practice
- 08 - Family Practice
- 11 - Internal Medicine
- 16 - Obstetrics/Gynecology
- 37 - Pediatric Medicine
- 38 - Geriatric Medicine
- 42 - Certified Nurse Midwife
- 50 - Nurse Practitioner
- 89 - Certified Clinical Nurse Specialist
- 97 - Physician Assistant

Claims submitted by providers other than the specialty types noted above will be denied.

Additionally, for claims with dates of service on or after September 28, 2016, CMS will allow coverage for HBV screening only when submitted with one of the following Place of Service (POS) codes:

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
• 11 - Physician’s Office
• 19 - Off Campus Outpatient Hospital
• 22 - On Campus Outpatient Hospital
• 49 - Independent Clinic
• 71 - State or Local Public Health Clinic
• 81 - Independent Laboratory

Claims submitted without one of the POS codes noted above will be denied.

**Diagnosis Code Reporting Requirements**

For claims with dates of service on or after September 28, 2016, CMS will allow coverage for G0499 for HBV screening only when services are reported with both of the following diagnosis codes denoting high risk:

- Z11.59 - Encounter for screening for other viral disease
- Z72.89 - Other Problems related to life style.

For claims with dates of service on or after September 28, 2016, CMS will allow coverage for G0499 for subsequent visits, only when services are reported with the following diagnosis codes:

- Z11.59 and one of the high risk codes below
  - F11.10-F11.99
  - F13.10-F13.99
  - F14.10-F14.99
  - F15.10-F15.99
  - Z20.2
  - Z20.5
  - Z72.52
  - Z72.53

For claims with dates of service on or after September 28, 2016, CMS will allow coverage for HBV screening (CPT codes 86704, 86706, 87340 and 87341) in pregnant women only when services are reported with one of the following diagnosis codes:

- Z11.59 - Encounter for screening for other viral diseases, and one of the following
- Z34.00 - Encounter for supervision of normal first pregnancy, unspecified trimester
- Z34.80 - Encounter for supervision of other normal pregnancy, unspecified trimester
- Z34.90 - Encounter for supervision of normal pregnancy, unspecified, unspecified trimester
- O09.90 - Supervision of high risk pregnancy, unspecified, unspecified trimester

For claims with dates of service on or after September 28, 2016, CMS will allow coverage for HBV screening (CPT codes 86704, 86706, 87340, and 87341) in pregnant women at high risk only when services are reported with one of the following diagnosis codes:

- Z11.59 - Encounter for screening for other viral diseases; and
- Z72.89 - Other problems related to lifestyle, and also one of the following:

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z34.00</td>
<td>Encounter for supervision of normal first pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>Z34.01</td>
<td>Encounter for supervision of normal first pregnancy, first trimester</td>
</tr>
<tr>
<td>Z34.02</td>
<td>Encounter for supervision of normal first pregnancy, second trimester</td>
</tr>
<tr>
<td>Z34.03</td>
<td>Encounter for supervision of normal first pregnancy, third trimester</td>
</tr>
<tr>
<td>Z34.80</td>
<td>Encounter for supervision of other normal pregnancy, unspecified trimester</td>
</tr>
<tr>
<td>Z34.81</td>
<td>Encounter for supervision of other normal pregnancy, first trimester</td>
</tr>
<tr>
<td>Z34.82</td>
<td>Encounter for supervision of other normal pregnancy, second trimester</td>
</tr>
<tr>
<td>Z34.83</td>
<td>Encounter for supervision of other normal pregnancy, third trimester</td>
</tr>
<tr>
<td>Z34.90</td>
<td>Encounter for supervision of normal pregnancy, unspecified, unspecified trimester</td>
</tr>
<tr>
<td>Z34.91</td>
<td>Encounter for supervision of normal pregnancy, unspecified, first trimester</td>
</tr>
<tr>
<td>Z34.92</td>
<td>Encounter for supervision of normal pregnancy, unspecified, second trimester</td>
</tr>
<tr>
<td>Z34.93</td>
<td>Encounter for supervision of normal pregnancy, unspecified, third trimester</td>
</tr>
<tr>
<td>O09.90</td>
<td>Supervision of high risk pregnancy, unspecified, unspecified trimester</td>
</tr>
<tr>
<td>O09.91</td>
<td>Supervision of high risk pregnancy, unspecified, first trimester</td>
</tr>
<tr>
<td>O09.92</td>
<td>Supervision of high risk pregnancy, unspecified, second trimester</td>
</tr>
<tr>
<td>O09.93</td>
<td>Supervision of high risk pregnancy, unspecified, third trimester</td>
</tr>
</tbody>
</table>

Claim/Service Denial

When denying payment for HBV screening use, your MAC will use the appropriate Claim Adjustment Reason Codes (CARCs), Remittance Advice Remark Codes (RARCs), or group codes.

When denying services submitted on a TOB other than 13X, 14X, or 85X, they will use:
- CARC 170 - Payment is denied when performed/billed by this type of provider.
  Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present
- RARC N95 - This provider type/provider specialty may not bill this service
- Group Code CO (Contractual Obligation) - Assigning financial liability to the provider

When denying services when HCPCS G0499 is paid in history for claims with dates of service on and after September 28, 2016, or if the beneficiary’s claim history shows claim lines containing CPT codes 86704, 86706, 87340, and 87341 submitted in the previous 11 full months they will use the following messages:
- CARC 119 - “Benefit maximum for this time period or occurrence has been reached.”
- RARC N386 - “This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at [www.cms.gov/mcd/search.asp](http://www.cms.gov/mcd/search.asp). If you do not have web access, you may contact the contractor to request a copy of the NCD.”

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Group Code PR (Patient Responsibility) - Assigning financial responsibility to the beneficiary (if a claim is received with occurrence code 32 with or without GA modifier or a claim –line is received with a GA modifier indicating a signed ABN is on file).

Group Code CO (Contractual Obligation) - Assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file).

When denying services for G0499, when ICD-10 diagnosis code Z72.89 and Z11.59 are not present on the claim, MACs will use:

- CARC 167 - “This (these) diagnosis(es) is (are) not covered. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.”
- RARC N386 - This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.

Group Code CO

Denying services for HBV screening, HCPCS G0499, when ICD-10 diagnosis code Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93, O09.90, O09.91, O09.92, or O09.93 is present on the claim:

- CARC 167 – “This (these) diagnosis(es) is (are) not covered. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.”
- RARC N386 - This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.

Group Code: CO (Contractual Obligation)

When denying services for G0499 for subsequent visits, when ICD-10 diagnosis code Z11.59 and one of the following high risk diagnosis codes: F11.10- F11.19, F13.10 - F13.99, F14.10 - F14.99, F15.10 - F15.99, Z20.2, Z20.5, Z72.52, or Z72.53 are not present on the claim, MACs will use:

- CARC 167 - “This (these) diagnosis(es) is (are) not covered. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.”
- RARC N386 - This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.

Group Code CO

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
When denying claim lines for G0499 without the appropriate POS code, MACs will use:

- CARC 171 - Payment is denied when performed by this type of provider on this type of facility. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.
- RARC N428 - Not covered when performed in certain settings.
- Group Code CO

When denying claim lines for G0499 that are not submitted from the appropriate provider specialties, MACs will use:

- CARC 184 - The prescribing/ordering provider is not eligible to prescribe/order the service billed. NOTE: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.
- RARC N386 - “This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at http://www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.”
- Group Code PR (Patient Responsibility) - Assigning financial responsibility to the beneficiary (if a claim is received with a GA modifier indicating a signed ABN is on file).
- Group Code CO (Contractual Obligation) - Assigning financial liability to the provider (if a claim line-item is received with a GZ modifier indicating no signed ABN is on file).

When denying services where previous HBV screening, HCPCS 86704, 86706, 87340, or 87341, is paid during the same pregnancy period or more than two screenings are paid to women that are at high risk, they will use:

- CARC 119 - “Benefit maximum for this time period or occurrence has been reached.”
- RARC N362 - “The number of days or units of service exceeds our acceptable maximum.”
- RARC N386 - “This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.”
- Group Code PR (Patient Responsibility) - Assigning financial responsibility to the beneficiary (if a claim is received with a GA modifier indicating a signed ABN is on file).
- Group Code CO (Contractual Obligation) - Assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file).

When denying claim lines for HBV screening, HCPCS G0499 for a subsequent HBV screening test for non-pregnant, high risk beneficiary when a claim line for an initial HBV screening has not yet been posted in history, use the following messages:

- CARC B15 - This service/procedure requires that a qualifying service/procedure be received and covered. The qualifying other service/procedure has not been received/adjudicated. Note: Refer to the 835 Healthcare Policy Identification Segment (loop 2110 Service Payment Information REF), if present.
RARC N386 - This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.

Group Code - CO (Contractual Obligation).

When denying services for HBV screening, HCPCs 86704, 86706, 87340, and 87341 that are billed without the appropriate diagnosis code MACs will use:

- CARC 50 - These are non-covered services because this is not deemed a “medical necessity” by the payer. Note: Refer to the 835 Healthcare Policy identification Segment (loop 2110 Service Payment information REF), if present.

- RARC N386 - “This decision was based on a National Coverage Determination (NCD). An NCD provides a coverage determination as to whether a particular item or service is covered. A copy of this policy is available at www.cms.gov/mcd/search.asp. If you do not have web access, you may contact the contractor to request a copy of the NCD.”

- Group Code PR (Patient Responsibility) - Assigning financial responsibility to the beneficiary (if a claim is received with a GA modifier indicating a signed ABN is on file).

- Group Code CO (Contractual Obligation) - Assigning financial liability to the provider (if a claim is received with a GZ modifier indicating no signed ABN is on file).

Additional Notes

- HCPCS code G0499 will appear in the January 1, 2018, Clinical Laboratory Fee Schedule (CLFS), in the January 1, 2017, Integrated Outpatient Code Editor (IOCE), and in the January 1, 2017, Medicare Physician Fee Schedule (MPFS) with indicator ‘X’. HCPCS code G0499 will be effective retroactive to September 28, 2016, in the IOCE.

- Your MAC will not search for claims containing HCPCS G0499 with dates of service on or after September 28, 2016, but may adjust claims that you bring to their attention.

- You should be aware that the revision to the “Medicare National Coverage Determinations Manual” is a National Coverage Determination (NCD). NCDs are binding on all carriers, fiscal intermediaries, contractors with the Federal government that review and/or adjudicate claims, determinations, and/or decisions, quality improvement organizations, qualified independent contractors, the Medicare appeals council, and Administrative Law Judges (ALJs) (see 42 CFR Section 405.1060(a)(4) (2005)). An NCD that expands coverage is also binding on a Medicare advantage organization. In addition, an ALJ may not review an NCD. (See Section 1869(f)(1)(A)(i) of the Social Security Act.)

- MACs will apply contractor pricing to claim lines with G0499 with dates of service September 28, 2016, through December 31, 2017.

- Deductible and coinsurance do not apply to G0499.
Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/index.html under - How Does It Work.

Document History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 4, 2017</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
The Process of Prior Authorization

Note: This article was revised on May 1, 2017, to include a new Web address for the Required Prior Authorization List. All other information remains the same.

Provider Types Affected

This MLN Matters® Article is intended for providers ordering certain DMEPOS items and suppliers submitting claims to Medicare Administrative Contractors (MACs) for items furnished to Medicare beneficiaries.

What You Need to Know

Change Request (CR) 9940 updates the Centers for Medicare & Medicaid Services (CMS) “Program Integrity Manual” to permit the MACs to conduct prior authorization processes, as so directed by CMS through individualized operational instructions. As of January 2017, Prior Authorization of Certain Durable Medical Equipment, Prosthetic, Orthotic, and Supply Items, frequently subject to unnecessary utilization, is the only permanent (non-demonstration) prior authorization program approved for implementation. Make sure your billing staff is aware of these changes.

Background

Prior authorization is a process through which a request for provisional affirmation of coverage is submitted to a medical review contractor for review before the item or service is furnished to the beneficiary and before the claim is submitted for processing. It is a process that permits the submitter/requester (for example, provider, supplier, beneficiary) to send in
medical documentation, in advance of the item or service being rendered, and subsequently billed, in order to verify its eligibility for Medicare claim payment.

For any item or service to be covered by Medicare it must:

- Be eligible for a defined Medicare benefit category
- Be medically reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member
- Meet all other applicable Medicare coverage, coding and payment requirements

Contractors shall, at the direction of CMS or other authorizing entity, conduct prior authorizations and alert the requester/submitter of any potential issues with the information submitted.

A prior authorization request decision can be either a provisional affirmative or a non-affirmative decision.

- A provisional affirmative decision is a preliminary finding that a future claim submitted to Medicare for the item or service likely meets Medicare’s coverage, coding, and payment requirements.
- A non-affirmative decision is a finding that the submitted information/documentation does not meet Medicare’s coverage, coding, and payment requirements, and if a claim associated with the prior authorization is submitted for payment, it would not be paid. MACs shall provide notification of the reason for the non-affirmation, if a request is non-affirmative, to the submitter/requester. If a prior authorization request receives a non-affirmative decision, the prior authorization request can be resubmitted an unlimited number of times.
- Prior authorization may also be a condition of payment. This means that claims submitted without an indication that the submitter/requester received a prior authorization decision (that is, Unique Tracking Number (UTN)) will be denied payment.

Each prior authorization program will have an associated Operational Guide that will be available on the CMS website. In addition, MACs will educate stakeholders each time a new prior authorization program is launched. That education will include the requisite information and timeframes for prior authorization submissions and the vehicle to be used to submit such information to the MAC.

**Prior Authorization Program for DME MACs**

A prior authorization program for certain Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) items that are frequently subject to unnecessary utilization is described in 42 CFR 414.234. Among other things, this section establishes a Master List of certain DMEPOS items meeting inclusion criteria and potentially subject to prior authorization. CMS will select Healthcare Common Procedure Coding System
(HCPCS) codes from the Prior Authorization Master List to be placed on the Required Prior Authorization List, and such codes will be subject to prior authorization as a condition of payment. In selecting HCPCS codes, CMS may consider factors such as geographic location, item utilization or cost, system capabilities, administrative burden, emerging trends, vulnerabilities identified in official agency reports, or other data analysis.

- The Prior Authorization Master List is the list of DMEPOS items that have been identified using the inclusion criteria described in 42 CFR 414.234.
- The List of Required DMEPOS Prior Authorization Items contains those items selected from the Prior Authorization Master List to be implemented in the Prior Authorization Program. The List of Required DMEPOS Prior Authorization Items will be updated as additional codes are selected for prior authorization.
- CMS may suspend prior authorization requirements generally or for a particular item or items at any time and without undertaking rulemaking. CMS provides notification of the suspension of the prior authorization requirements via Federal Register notice and posting on the CMS prior authorization website.

The items on the Required Prior Authorization List, a “CMS Final Rule 6050-F” subpage containing the Master List, as well as other pertinent information and supporting documents regarding this program, are available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/DMEPOS/Prior-Authorization-Process-for-Certain-Durable-Medical-Equipment-Prosthetic-Orthotics-Supplies-Items.html.

**Additional Information**


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

**Document History**

- January 20, 2017 - Initial article released.
- May 1, 2017 - Article revised to include new Web address for the Required Prior Authorization List. All other information remains the same.
I N F O R M A T I O N  O N  W E B S I T E

WPS GHA publishes Local Coverage Determinations (LCDs) on its website: 
https://www.wpsgha.com/wps/portal/mac/site/policies/home

If you cannot gain access to the Internet from your office or home, you might try one of the many public libraries that offer Internet access. You may request a hard copy of a retired LCD by writing to our Freedom of Information (FOI) Unit.

WPS GHA
Attn: Freedom of Information Act (FOIA)
P.O. Box 7877
Madison, WI 53708-8788

NEW POLICIES

The following are new policies. Be sure to note the effective date of the new policy, as the policy will not appear as an active policy until the effective date. Prior to the effective date, the policy can be found by selecting the link "Display Future Effective Documents" within the CMS Medicare Coverage Database (MCD):

Visit our website at the appropriate link below for more information:

June 2017

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>MolDX: 4Kscore Assay</td>
<td>L37013</td>
<td>MolDX-023</td>
<td>07/17/2017</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX-CDD: ConfirmMDx Epigenetic Molecular Assay</td>
<td>L37005</td>
<td>MolDX-020</td>
<td>07/17/2017</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Chromosome 1p/19q Deletion Analysis</td>
<td>L37009</td>
<td>MolDX-021</td>
<td>07/17/2017</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: HLA-DQB1*06:02 Testing for Narcolepsy</td>
<td>L37003</td>
<td>MolDX-019</td>
<td>07/17/2017</td>
</tr>
</tbody>
</table>
May 2017
There are no new Policies/Articles for May 2017

April 2017
There are no new Policies/Articles for April 2017

March 2017
There are no new policies/articles for March 2017

**RETIRED POLICIES**

The following are retired policies. Be sure to note the effective date of the retired policy, as the policy will not appear as retired until the effective date.

Visit our website at the appropriate link below for more information:

June 2017
There are no retired Policies/Articles for June 2017

May 2017
There are no retired Policies/Articles for May 2017

April 2017
There are no retired Policies/Articles for April 2017

March 2017
There are no retired policies/articles for March 2017

**REVISED POLICIES**

The following are revised policies. Be sure to note the effective date of the revised policy, as the policy will not appear as an active policy until the effective date. Prior to the effective date, the policy can be found by selecting the link "Display Future Effective Documents" within the CMS Medicare Coverage Database (MCD):

Visit our website at the appropriate link below for more information:

June 2017
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Chemotherapy Drugs and their Adjuncts</td>
<td>L35053</td>
<td>HONC-010</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>Added to C. 27. Paclitaxel protein-bound particles/Abraxane (J9264) Per NCCN: Bladder Cancer-Upper GU Tract Tumors: Used as a single agent as subsequent systemic therapy for metastatic disease as an alternate regimen for select patients. C65.1 right renal pelvis C65.2 left renal pelvis C66.1 right ureter C66.2 left ureter. Effective Date 06/01/2017.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Added to C. 29. Pembrolizumab (Keytruda) (J9271) Is indicated for the treatment of adult and pediatric patients with refractory Classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. (C81.11-C81.19, C81.21-C81.29, C81.31-C81.39, C81.41-81.49, C81.91-C81.99, Z85.71). FDA approval 03/14/2017. Effective date 03/14/2017. Is indicated for palliative therapy as a single agent for relapsed or refractory disease in older adults (age 60 and greater). (C81.11-C81.19, C81.21-C81.29, C81.31-C81.39, C81.41-81.49, C81.91-C81.99, Z85.71). FDA approval 03/14/2017. Effective date 03/14/2017.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Electrocardiographic (EKG or ECG) Monitoring (Holter or Real-Time Monitoring)</td>
<td>L34636</td>
<td>CV-016</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>Added diagnosis code G45.9 (Transient cerebral ischemic attack, unspecified) to Group 1 Memory Loop recordings (codes 93268, 93270, 93271 and 93272), to Group 2 Other up to 48-hour recordings (codes 93224, 93225, 93226, 93227, 93228, and 93229) and to Group 3 More than 48 hours up to 21 day recordings (codes 0295T, 0296T, 0297T and 0298T).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Independent Diagnostic Testing Facilities- physician supervision and technician requirements</td>
<td>A54953</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>Added CPT code 72159: Magnetic resonance angiography, spinal canal and contents with or without contrast material: Radiologist and Certified Radiologic Technologist (ARRT:R.T.-MR) or ARMRIT-RT-MR. Added CPT code 73225: Magnetic resonance angiography, upper extremity, with or without contrast material: Radiologist and Certified Radiologic Technologist (ARRT:R.T.-MR) or ARMRIT-RT-MR.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: ENG and ACVRL1 Gene Tests Coding and Billing Guidelines</td>
<td>A55159</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added: For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract</td>
<td>Policy Title</td>
<td>CMS MCD Policy #</td>
<td>WPS Policy #</td>
<td>Effective Date</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: FANCC Genetic Testing Coding and Billing Guidelines</td>
<td>A55160</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added: For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information. Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types: o Loop 2400 or SV101-7 for the 5010A1 837P o Box 19 for paper claim Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types: o Line SV202-7 for 837I electronic claim o Block 80 for the UB04 claim form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Fragile X Coding and Billing Guidelines Update</td>
<td>A55163</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added: For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information. Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types: o Loop 2400 or SV101-7 for the 5010A1 837P o Box 19 for paper claim Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types: o Line SV202-7 for 837I electronic claim o Block 80 for the UB04 claim form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract</td>
<td>Policy Title</td>
<td>CMS MCD Policy #</td>
<td>WPS Policy #</td>
<td>Effective Date</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: GBA Genetic Testing Coding and Billing Guidelines</td>
<td>A55164</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
</tbody>
</table>
|          | The following instructions for claim submission were added: For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information. Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:  
  o Loop 2400 or SV101-7 for the 5010A1 837P  
  o Box 19 for paper claim Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:  
  o Line SV202-7 for 837I electronic claim  
  o Block 80 for the UB04 claim form |
| J5/J8    | MolDX: HAX1 Gene Sequencing Coding and Billing Guidelines | A55165 | NA | 06/01/2017 |
|          | The following instructions for claim submission were added: For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information. Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:  
  o Loop 2400 or SV101-7 for the 5010A1 837P  
  o Box 19 for paper claim Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:  
  o Line SV202-7 for 837I electronic claim  
  o Block 80 for the UB04 claim form |
| J5/J8    | MolDX: HERmark® Assay by Monogram | A55167 | NA | 06/01/2017 |
|          | The following instructions for claim submission were added:  
  • For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information. Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:  
  o Loop 2400 or SV101-7 for the 5010A1 837P  
  o Box 19 for paper claim |
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>MolDX: MammaPrint Billing and Coding Guidelines Update</td>
<td>A55175</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Loop 2400 or SV101-7 for the 5010A1 837P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Box 19 for paper claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Line SV202-7 for 837I electronic claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Block 80 for the UB04 claim form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Oncotype DX® Colon Cancer Assay Update</td>
<td>A55231</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Loop 2400 or SV101-7 for the 5010A1 837P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Box 19 for paper claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Line SV202-7 for 837I electronic claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Block 80 for the UB04 claim form</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Progensa® PCA3 Assay Coverage Update</td>
<td>A55202</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract</td>
<td>Policy Title</td>
<td>CMS MCD Policy #</td>
<td>WPS Policy #</td>
<td>Effective Date</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: STAT3 Gene Testing Coding and Billing Guidelines</td>
<td>A55209</td>
<td>NA</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Added Part B to the sentence below:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Loop 2400 or SV101-7 for the 5010A1 837P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Box 19 for paper claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The following instructions for claim submission were added:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For CPT non-NOC codes, Labs may either use the SV101-7 or SV202-7 (preferred) or the NTE field to submit this required information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Loop 2400 or SV101-7 for the 5010A1 837P</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Box 19 for paper claim</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Non-Invasive Peripheral Venous Vascular and Hemodialysis Access Studies</td>
<td>L35751</td>
<td>CV-047</td>
<td>06/01/2017</td>
</tr>
<tr>
<td></td>
<td>Added the following diagnosis codes to Group 1 for Peripheral Venous Examinations (93970 and 93971):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>I82.4Y1 Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract</td>
<td>Policy Title</td>
<td>CMS MCD Policy #</td>
<td>WPS Policy #</td>
<td>Effective Date</td>
</tr>
<tr>
<td>----------</td>
<td>--------------</td>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>J5/J8</td>
<td>Self-Administered Drug Exclusion List (SAD List)</td>
<td>A52800</td>
<td>NA</td>
<td>07/16/2017</td>
</tr>
</tbody>
</table>

Added the following sentence to the article text: Please note: some drugs may be listed more than once, using a different code, on the CPT/HCPCS coding table. Added J3590 Dupilmub (Dupixent); J3590 Brodalumab (Siliq); C9399 to code J3490 Tesamorelin (Egrifta®); C9399, J3490, and J3590 to code Q3028 for Interferon Beta-1A 1 mcg (Rebif®); trade names Quadmix (+Atropine) to Trimix J3490; and descriptor brand name of Papaverine HCL to J2440; all effective 07/16/2017. Removed J0272 Alprostadil urethral suppository (Muse®) (since it is a suppository); J2760 Phentolamine mesylate up to 5mg (Regitine) (since not self administered); J3310 Perphenazine up to 5mg (Perphenazine) (since it is no longer available in the US); J3590 Efalizumab (Raptiva®) (since it is off the US market); J1562 Immune Globulin (Vivaglobin®) (since it is not being manufactured anymore); and J3490 Nitroglycerine Lingual spray (Nitrolingual, Nitromist) (since it is not an injection); all effective 07/16/2017.

| J5/J8    | Zika Virus Testing by PCR and ELISA Methods | A55339 | NA | 06/01/2017 |

Article Guidance: Removed the expiration date of March 30, 2017 from modifier-22. The statement now reads:
*The use of modifier -22 is a temporary measure to allow for added payment to help offset the costs of the specific handling requirements of the FDA Emergency Use Authorization (EUA) and CDCP guidance. This exception will expire when a CPT® or Medicare procedure code is issued or when the FDA EUA is rescinded, whichever is sooner.
### May 2017

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Allergy Testing</td>
<td>L36402</td>
<td>ALRG-004</td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added code K20.0 (Eosinophilic esophagitis) to Groups 1 and 3. Added the phrase &quot;eosinophilic esophagitis&quot; to the Indication A.1.b. for Foods under Percutaneous Testing. A. In vivo testing (skin tests): this testing correlates the performance and evaluation of selective cutaneous and mucous membrane tests with the patient’s history, physician examination, and other observations.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Percutaneous Testing (scratch, puncture, prick) and is used to evaluate immunoglobulin E (IgE) mediated hypersensitivity. Percutaneous tests require medical supervision, since there is a small but significant risk of anaphylaxis. Overall, skin testing is quick, safe, and cost-effective. It remains the test of choice in most clinical situations where immediate hypersensitivity reactions are suspected.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Percutaneous testing is the usual preferred method for allergy testing. Medicare covers percutaneous (scratch, prick or puncture) testing when IgE-mediated reactions occur with any of the following:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>a. Inhalants.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Foods. (Patients present with signs and symptoms such as urticarial, angioedema, eosinophilic esophagitis, or anaphylaxis after ingestion of specific foods. Testing for food allergies in patients who present with wheezing is occasionally required.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>c. Hymenoptera (stinging insects).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>d. Specific drugs (penicillins, macromolecular agents, enzymes, and egg-containing vaccines). Skin testing is unreliable with other drugs.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Colonoscopy and Sigmoidoscopy- Diagnostic</td>
<td>L34614</td>
<td>GI-006</td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added to Indications and Limitations of Coverage and/or Medical Necessity A. The following are Medicare-covered indications for diagnostic colonoscopy: 2. d. Positive stool DNA test results.(e.g. guaiac/Fecal immunochemical test{FIT Test}/Cologuard).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Immunizations</td>
<td>L34596</td>
<td>ALRG-003</td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Added the phrase &quot;for tetanus&quot; to the following statement. Each specific immunization has specific coverage criteria. The following immunizations are covered post-exposure:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. Tetanus, Diphtheria and Pertussis (Tdap) Vaccines and Tetanus Diphtheria (Td) Vaccines</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>These injections are covered when given for an acute injury to a person who is incompletely immunized for tetanus.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Independent Diagnostic Testing Facilities – Physician Supervision and Technician Requirements</td>
<td>A54953</td>
<td>NA</td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CPT Code 75635: Added the Certified Radiologic Technologist (ARRT:R.T.-CT).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>Mohs Micrographic Surgery - Billing and Coding Guideline</td>
<td>L35494</td>
<td>DERM-010</td>
<td>05/01/2017</td>
</tr>
<tr>
<td>Contract</td>
<td>Policy Title</td>
<td>CMS MCD Policy #</td>
<td>WPS Policy #</td>
<td>Effective Date</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------</td>
<td>------------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td></td>
<td>Added POS 31 (skilled nursing facility) to the Billing and Coding Guidelines, effective 05/01/2017: Claims for Mohs surgery services are payable under Medicare Part B in the following places of service: office (11), off-campus outpatient hospital (19), inpatient hospital (21), on-campus outpatient hospital (22), ambulatory surgery center (24), skilled nursing facility (31), independent clinic (49), federally qualified health center (50), state or local public health clinic (71) and rural health clinic (72).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Biomarkers in Cardiovascular Risk Assessment</td>
<td>L36523</td>
<td>MolDX-003</td>
<td>05/01/2017</td>
</tr>
<tr>
<td></td>
<td>The Contractor Determination Number: CV-050 is being changed to MolDX-003. Added Note #1 and renumbered previous Note #1 to Note #2: Note #1: There is no Medicare benefit for screening CV risk assessment testing for asymptomatic (without signs or symptoms of disease) patients. Screening asymptomatic patients for cardiovascular risk is statutorily excluded by Medicare and will not be addressed in this policy. Updated the source of Information section with: American Heart Association. AHA Recommendation: Homocysteine, Folic Acid and Cardiovascular Risk. National Academy of Clinical Biochemistry: Laboratory Medicine Practice Guidelines, Emerging biomarkers for primary prevention of cardiovascular disease and stroke. April 2009. The following information was removed under these headings: <strong>Lipoprotein(a) (Lp(a))</strong> Removed: Due to the level of evidence, there will be no coverage for intermediate risk because there is no data to suggest that more aggressive risk factor modification improves patient health outcomes. <strong>Summary of Lipoprotein Testing</strong> Removed: Consequently, lipoprotein testing is considered investigational and not covered.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: Molecular RBC Phenotyping</td>
<td>L36795</td>
<td>MolDX-012</td>
<td>06/15/2017</td>
</tr>
<tr>
<td></td>
<td>Added 0001U CPT code and removed CPT 81403. CPT/HCPCS Codes Group 1 Paragraph: Group 1 Codes 0001U Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: MCOLN1 Genetic Testing Coding and Billing Guidelines</td>
<td>A55176</td>
<td>NA</td>
<td>05/01/2017</td>
</tr>
</tbody>
</table>
The following claims submission information was added:
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Box 19 for paper claim
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:
  - Line SV202-7 for 837I electronic claim
  - Block 80 for the UB04 claim form


<table>
<thead>
<tr>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>A55209</td>
<td>NA</td>
<td>05/01/2017</td>
</tr>
</tbody>
</table>

The following claims submission information was added:
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part B claim field/types:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Box 19 for paper claim
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:
  - Line SV202-7 for 837I electronic claim
  - Block 80 for the UB04 claim form

**April 2017**

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Allergy Immunotherapy</td>
<td>L36408</td>
<td>ALRG-005</td>
<td>04/01/2017</td>
</tr>
</tbody>
</table>

Added the Group 1 Paragraph: Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book. Added statement to Indications #8. Rush desensitization can also be used in select patients with stinging insect allergies. Added the following diagnosis codes to Group 3 for Rapid Desensitization: 95180.

- T63.421A Toxic effect of venom of ants, accidental (unintentional), initial encounter
- T63.421D Toxic effect of venom of ants, accidental (unintentional), subsequent encounter
- T63.421S Toxic effect of venom of ants, accidental (unintentional), sequela
- T63.422A Toxic effect of venom of ants, intentional self-harm, initial encounter
- T63.422D Toxic effect of venom of ants, intentional self-harm, subsequent encounter
- T63.422S Toxic effect of venom of ants, intentional self-harm, sequela
- T63.423A Toxic effect of venom of ants, assault, initial encounter
- T63.423D Toxic effect of venom of ants, assault, subsequent encounter
- T63.423S Toxic effect of venom of ants, assault, sequela
- T63.424A Toxic effect of venom of ants, undetermined, initial encounter
- T63.424D Toxic effect of venom of ants, undetermined, subsequent encounter
- T63.424S Toxic effect of venom of ants, undetermined, sequela
- T63.441A Toxic effect of venom of bees, accidental (unintentional), initial encounter
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>encounter</td>
<td>T63.441D</td>
<td>Toxic effect of venom of bees, accidental (unintentional), subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.441S</td>
<td>Toxic effect of venom of bees, accidental (unintentional), sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.442A</td>
<td>Toxic effect of venom of bees, intentional self-harm, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.442B</td>
<td>Toxic effect of venom of bees, intentional self-harm, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.442S</td>
<td>Toxic effect of venom of bees, intentional self-harm, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.443A</td>
<td>Toxic effect of venom of bees, assault, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.443B</td>
<td>Toxic effect of venom of bees, assault, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.443S</td>
<td>Toxic effect of venom of bees, assault, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.444A</td>
<td>Toxic effect of venom of bees, undetermined, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.444B</td>
<td>Toxic effect of venom of bees, undetermined, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.444S</td>
<td>Toxic effect of venom of bees, undetermined, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.451A</td>
<td>Toxic effect of venom of hornets, accidental (unintentional), initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.451B</td>
<td>Toxic effect of venom of hornets, accidental (unintentional), subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.451S</td>
<td>Toxic effect of venom of hornets, accidental (unintentional), sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.452A</td>
<td>Toxic effect of venom of hornets, intentional self-harm, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.452B</td>
<td>Toxic effect of venom of hornets, intentional self-harm, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.452S</td>
<td>Toxic effect of venom of hornets, intentional self-harm, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.453A</td>
<td>Toxic effect of venom of hornets, assault, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.453B</td>
<td>Toxic effect of venom of hornets, assault, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.453S</td>
<td>Toxic effect of venom of hornets, assault, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.454A</td>
<td>Toxic effect of venom of hornets, undetermined, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.454B</td>
<td>Toxic effect of venom of hornets, undetermined, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.454S</td>
<td>Toxic effect of venom of hornets, undetermined, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.461A</td>
<td>Toxic effect of venom of wasps, accidental (unintentional), initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.461B</td>
<td>Toxic effect of venom of wasps, accidental (unintentional), subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.461S</td>
<td>Toxic effect of venom of wasps, accidental (unintentional), sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.462A</td>
<td>Toxic effect of venom of wasps, intentional self-harm, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.462B</td>
<td>Toxic effect of venom of wasps, intentional self-harm, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.462S</td>
<td>Toxic effect of venom of wasps, intentional self-harm, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.463A</td>
<td>Toxic effect of venom of wasps, assault, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.463B</td>
<td>Toxic effect of venom of wasps, assault, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.463S</td>
<td>Toxic effect of venom of wasps, assault, sequela</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.464A</td>
<td>Toxic effect of venom of wasps, undetermined, initial encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.464B</td>
<td>Toxic effect of venom of wasps, undetermined, subsequent encounter</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>T63.464S</td>
<td>Toxic effect of venom of wasps, undetermined, sequela</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

J5/J8 Drug Administration Coding | A54176 | N/A | 05/16/2017
### Contract J5/J8

**Policy Title:** Drugs and Biologics (Non-chemotherapy) & Billing and Coding Guidelines  
**CMS MCD Policy #** L34741  
**WPS Policy #** INJ-041  
**Effective Date** 04/01/2017  

Added natalizumab, Tysabri, J2323 to the list of drugs that should not be billed using a chemotherapy administration code. Corrected spelling error of Stelara®.  

<table>
<thead>
<tr>
<th>Group 4 Paragraph</th>
<th>J2778 Ranibizumab (Lucentis™), 0.1 mg</th>
<th>Myopic Choroidal Neovascularization (mCNV) FDA approval 01/05/2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>H44.21:</td>
<td>Degenerative myopia, right eye</td>
<td></td>
</tr>
<tr>
<td>H44.22:</td>
<td>Degenerative myopia, left eye</td>
<td></td>
</tr>
<tr>
<td>H44.23:</td>
<td>Degenerative myopia, bilateral</td>
<td></td>
</tr>
<tr>
<td>H35.051:</td>
<td>Retinal neovascularization, unspecified, right eye</td>
<td></td>
</tr>
<tr>
<td>H35.052:</td>
<td>Retinal neovascularization, unspecified, left eye</td>
<td></td>
</tr>
<tr>
<td>H35.053:</td>
<td>Retinal neovascularization, unspecified, bilateral</td>
<td></td>
</tr>
</tbody>
</table>

**Documentations Requirements:**  
The medical record must include the following information:  
A physician’s order with appropriate signature;  
Supervising physician with appropriate signature;  
Medication Administration record with appropriate signature  

Effective 01/01/2017 claims for unused drugs or biologicals from single use vials or single use packages that are opened and the entire dose/quantity is not administered and the remainder is discarded shall be submitted using the JW modifier. See Billing & Coding Guidelines.  

**Billing & Coding Guidelines Medicare Excerpts**  
   - Claims for discarded drugs or biologicals amount not administered to any patient shall be submitted using the JW modifier. Unused drugs or biologicals from single use vials or single use packages that are opened and the entire dose/quantity is not administered and the remainder is discarded. (except those provided under the Competitive Acquisition Program (CAP) for Part B drugs and biologicals).  
   - Providers must document the discarded drugs or biologicals in the patient's medical record.  
   - This modifier, billed on a separate line, will provide payment for the amount of discarded drugs or biologicals.  

See CR 9603  

**Contract J5/J8**  
**Policy Title:** Independent Diagnostic Testing Facilities: Physician Supervision and Technician Requirements  
**CMS MCD Policy #** A54953  
**WPS Policy #** NA  
**Effective Date** 04/01/2017  

Added additional Board Certification: National Center for Competency Testing for ECG Technician (NCET).  
Updated the technician requirements for codes 93000 & 93005 to include NCET-ECG Tech.
### MolDX: Molecular Diagnostic Tests (MDT)

**Policy Title:** MolDX: Molecular Diagnostic Tests (MDT)

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>MolDX: Molecular Diagnostic Tests (MDT)</td>
<td>L36807</td>
<td>MolDX-004</td>
<td>05/16/2017</td>
</tr>
</tbody>
</table>

Added the following CPT codes to this LCD effective 05/16/2017:

**CPT/HCPCS Codes**

**Group 1 Paragraph:**

**Group 1 Codes**

- 0001U Rbc dna hea 35 ag 11 bld grp
- 0002U Onc clrct 3 ur metab alg plp
- 0003U Onc ovar 5 prtn ser alg scor
- 86152 cell enumeration & id
- 86153 cell enumeration phys interp
- 86505-86507 Microbiology

CPT codes 88380 and 88381 will no longer require a DEX-Z Code™ and have been removed from this policy. This change is effective 04/01/2017.

### Non-Coronary Vascular Stents

**Contract:**

- J5/J8

**Policy Title:** Non-Coronary Vascular Stents

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Non-Coronary Vascular Stents</td>
<td>L35998</td>
<td>CV-049</td>
<td>04/01/2017</td>
</tr>
</tbody>
</table>

Added the following diagnosis codes to Group 5 for venous codes 37238 and 37239:

- I82.411 Acute embolism and thrombosis of right femoral vein
- I82.412 Acute embolism and thrombosis of left femoral vein
- I82.413 Acute embolism and thrombosis of femoral vein, bilateral
- I82.421 Acute embolism and thrombosis of right iliac vein
- I82.422 Acute embolism and thrombosis of left iliac vein
- I82.423 Acute embolism and thrombosis of iliac vein, bilateral

### Chemotherapy Drugs and their Adjuncts

**Contract:**

- J5/J8

**Policy Title:** Chemotherapy Drugs and their Adjuncts

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Chemotherapy Drugs and their Adjuncts</td>
<td>L35053</td>
<td>HONC-010</td>
<td>03/01/2017</td>
</tr>
</tbody>
</table>

C. 17. Ipilimumab (Yervoy™)(J9228)

Malignant melanoma of skin (C43.10, C43.20, C43.30, C43.60, C43.70, C43.9, C69.90-C69.92) Effective 03/02/2017.

C. 17. Ipilimumab (Yervoy™)(J9228)

Per NCCN: Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. FDA approval 10/28/2015

- for stage III sentinel lymph node positive metastasis >1 mm following a complete lymph node dissection
- for stage III disease with clinically positive node(s) following wide excision of primary tumor and a complete therapeutic lymph node dissection
- following complete lymph node dissection and/or complete resection of nodal recurrence.
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>Electrocardiographic (EKG or ECG) Monitoring (Holter or Real-Time Monitoring)</td>
<td>L34636</td>
<td>CV-016</td>
<td>03/01/2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>J5/J8</td>
<td>MolDX: FDA-Approved EGFR Tests</td>
<td>A55193</td>
<td>NA</td>
<td>03/01/2017</td>
</tr>
</tbody>
</table>

For clarification, added the following paragraphs: Group 1 Paragraph: Memory Loop recordings (codes 93268, 93270, 93271 and 93272); added Group 2 Paragraph: Other up to 48-hour recordings (codes 93224, 93225, 93226, 93227, 93228, and 93229); and added Group 3 Paragraph: More than 48 hours up to 21 day recordings (codes 0295T, 0296T, 0297T and 0298T).

The following information has been added to this article:

1. Effective 6/01/16
cobas EGFR Mutation Test is a real-time PCR test for the qualitative
detection of defined mutations of the epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients. Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffinembedded tumor tissue (FFPET) or circulating-free tumor DNA (cfDNA) from plasma derived from EDTA anticoagulated peripheral whole blood.

The test is indicated as a companion diagnostic to aid in selecting NSCLC patients for treatment with the targeted therapies listed in the Table below in accordance with the approved therapeutic product labeling:

<table>
<thead>
<tr>
<th>Drug</th>
<th>FFPET</th>
<th>Plama</th>
</tr>
</thead>
<tbody>
<tr>
<td>TARCEVA® (erlotinib)</td>
<td>Exon 19 deletions and L858R</td>
<td>Exon 19 deletions and L858R</td>
</tr>
<tr>
<td>TAGRISSO™ (osimertinib)</td>
<td>T790M</td>
<td>NA</td>
</tr>
</tbody>
</table>

Patients with positive cobas® EGFR Mutation Test v2 test results using plasma specimens for the presence of EGFR exon 19 deletions or L858R mutations are eligible for treatment with TARCEVA® (erlotinib). Patients who are negative for these mutations by this test should be reflexed to routine biopsy and testing for EGFR mutations with the FFPET sample type.

Enter DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:
- Line SV202-7 for 837I electronic claim
- Block 80 for the UB04 claim form

Group 3 Paragraph: CPT codes CYP2C9 and VKORC1 are non-covered for all indications per this policy. However, CYP2C9 and VKORC1 can be covered in accordance with NCD 90.1 and should be reported with HCPCS code G9143 warfarin responsiveness testing.

Group 3 Codes:
- 81227 CYP2C9 (CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 9) (EG, DRUG METABOLISM), GENE
- 81355 VKORC1 (VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1) (EG, WARFARIN METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, -1639/3673)

Group 4 Paragraph: CYP gene panels (testing for more than 1 CYP gene on same date of service) is a single unit of service (UOS=1). All CYP panels should be billed with 81479 and are non-covered.

Group 4 Codes:
- 81479 Unlisted Molecular Pathology Procedure
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>MolDX: MMACHC Test Coding and Billing Guidelines</td>
<td>A55191</td>
<td>NA</td>
<td>03/01/2017</td>
</tr>
</tbody>
</table>

The following instructions for Part A claim submission were added. Enter DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:

- Line SV202-7 for 837I electronic claim
- Block 80 for the UB04 claim form

<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>J5/J8</td>
<td>MolDX: NRAS Genetic Testing</td>
<td>L36797</td>
<td>MolDX-013</td>
<td>03/01/2017</td>
</tr>
</tbody>
</table>

The following information was added to the policy:

**ICD-10 Codes that Support Medical Necessity**

**Group 1 Paragraph: Although not specifically addressed in the ICD-10-CM Official Guidelines for Coding and Reporting 2016, when an encounter is for management of a complication associated with a neoplasm (NRAS testing for metastatic colon cancer), the complication (metastasis) is coded first, followed by the appropriate codes for the neoplasm.**

*Primary Diagnoses are listed in Group 1 and Secondary Diagnoses in Group 2.

**Group 1 Codes:**

- C77.0-C77.5 Secondary and unspecified malignant neoplasm of lymph nodes
- C77.6 Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
- C77.7 Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
- C77.8 Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
- C77.9 Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions

- C78.00-C78.02 Secondary malignant neoplasm of unspecified lung,
  - Secondary malignant neoplasm of right lung
  - Secondary malignant neoplasm of left lung
- C78.1 Secondary malignant neoplasm of mediastinum
- C78.2 Secondary malignant neoplasm of pleura
- C78.30 Secondary malignant neoplasm of unspecified respiratory organ
- C78.39 Secondary malignant neoplasm of other respiratory organs
- C78.4 Secondary malignant neoplasm of small intestine
- C78.5-C78.7 Secondary malignant neoplasm of large intestine and rectum,
  - Secondary malignant neoplasm of retroperitoneum and peritoneum,
  - Secondary malignant neoplasm of liver and intrahepatic bile duct
- C78.80 Secondary malignant neoplasm of unspecified digestive organ
- C78.89 Secondary malignant neoplasm of other digestive organs
- C79.00 Secondary malignant neoplasm of unspecified kidney and renal pelvis
- C79.01 Secondary malignant neoplasm of right kidney and renal pelvis
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>C79.02</td>
<td>Secondary malignant neoplasm of left kidney and renal pelvis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.10</td>
<td>Secondary malignant neoplasm of unspecified urinary organs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.11</td>
<td>Secondary malignant neoplasm of bladder</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.19</td>
<td>Secondary malignant neoplasm of other urinary organs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.2</td>
<td>Secondary malignant neoplasm of skin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.31</td>
<td>Secondary malignant neoplasm of brain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.32</td>
<td>Secondary malignant neoplasm of cerebral meninges</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.40</td>
<td>Secondary malignant neoplasm of unspecified part of nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.49</td>
<td>Secondary malignant neoplasm of other parts of nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.51</td>
<td>Secondary malignant neoplasm of bone</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.52</td>
<td>Secondary malignant neoplasm of bone marrow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.60</td>
<td>Secondary malignant neoplasm of unspecified ovary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.61</td>
<td>Secondary malignant neoplasm of right ovary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.62</td>
<td>Secondary malignant neoplasm of left ovary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.70</td>
<td>Secondary malignant neoplasm of unspecified adrenal gland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.71</td>
<td>Secondary malignant neoplasm of right adrenal gland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.72</td>
<td>Secondary malignant neoplasm of left adrenal gland</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.81</td>
<td>Secondary malignant neoplasm of breast</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.82</td>
<td>Secondary malignant neoplasm of genital organs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.89</td>
<td>Secondary malignant neoplasm of other specified sites</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C79.9</td>
<td>Secondary malignant neoplasm of unspecified site</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Group 2 Paragraph:** Secondary Diagnoses

**Group 2 Codes:**

- C18.0-C18.9 Malignant neoplasm of cecum
  - Malignant neoplasm of appendix
  - Malignant neoplasm of ascending colon
  - Malignant neoplasm of hepatic flexure
  - Malignant neoplasm of transverse colon
  - Malignant neoplasm of splenic flexure
  - Malignant neoplasm of descending colon
  - Malignant neoplasm of sigmoid colon
  - Malignant neoplasm of overlapping sites of colon
  - Malignant neoplasm of colon, unspecified

- C19 Malignant neoplasm of rectosigmoid junction
- C20 Malignant neoplasm of rectum

**J5/J8 MolDX: TP53 Gene Test Coding and Billing Guidelines**

- MolDX Protocol Code: A55221
- Effective Date: 03/01/2017

The following instructions for Part A claim submission were added. Enter DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:

- Line SV202-7 for 837I electronic claim
- Block 80 for the UB04 claim form

**J5/J8 MolDX: UGT1A1 Gene Analysis Coding and Billing Guidelines**

- MolDX Protocol Code: A55222
- Effective Date: 03/01/2017

The following instructions for Part A claim submission were added.
<table>
<thead>
<tr>
<th>Contract</th>
<th>Policy Title</th>
<th>CMS MCD Policy #</th>
<th>WPS Policy #</th>
<th>Effective Date</th>
</tr>
</thead>
</table>
| J5/J8   | Enter DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:  
  - Line SV202-7 for 837I electronic claim  
  - Block 80 for the UB04 claim form | | A55232 | NA | 03/01/2017 |
| J5/J8   | MolDX: VEGFR2 Tests Coding and Billing Guidelines | | | | 03/01/2017 |
| J5/J8   | The following information was added to the policy:  
  Enter DEX Z-Code™ identifier adjacent to the CPT code in the comment/narrative field for the following Part A claim field/types:  
  - Line SV202-7 for 837I electronic claim  
  - Block 80 for the UB04 claim form | | | | 03/01/2017 |
| J5/J8   | Polysomnography and Other Sleep Studies | L36839 | NEURO-018 | 03/01/2017 |
| J5/J8   | Added 2 ICD-10 codes to Group 2 Paragraph: 95782, 95807, 95808 and 95810  
Covered for:  
Group 2 Codes:  
F51.3 Sleepwalking, (somnambulism) and  
F51.4 Sleep terrors, (night terrors). | | | | 03/01/2017 |
General Information

New Physician Specialty Code for Advanced Heart Failure and Transplant Cardiology, Medical Toxicology, and Hematopoietic Cell Transplantation and Cellular Therapy

Provider Types Affected

This MLN Matters® Article is intended for physicians and providers submitting claims to Medicare Administrative Contractors (MACs) for services to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9957 establishes new physician specialty codes for Advanced Heart Failure and Transplant Cardiology (C7), Medical Toxicology (C8), and Hematopoietic Cell Transplantation and Cellular Therapy (C9). The new codes are effective on October 1, 2017. Make sure that your billing staffs are aware of these new specialty codes.

Background

Physicians self-designate their Medicare physician specialty on the Medicare enrollment application (CMS-855I or CMS-855O) or Internet-based Provider Enrollment, Chain and Ownership System (PECOS) when they enroll in the Medicare program. Medicare physician specialty codes describe the specific/unique types of medicine that physicians (and certain other suppliers) practice. The Centers for Medicare & Medicaid Services (CMS) uses specialty codes for programmatic and claims processing purposes.

The CMS-855I and CMS-855O paper applications will be updated to reflect the new specialties in the future. In the interim, providers shall select the ‘Undefined physician type’
option on the enrollment application and specify the applicable specialty in the space provided.

Existing enrolled providers who want to update their specialty to reflect one of the new specialties must submit a change of information application to their MAC. Providers may submit an enrollment application to initially enroll or update their specialty within 60 days of the implementation date of the new specialties.

**Additional Information**


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

---

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Remittance Advice Remark Code (RARC), Claims Adjustment Reason Code (CARC), Medicare Remit Easy Print (MREP) and PC Print Update

Provider Types Affected

This MLN Matters® Article is intended for physicians, other providers, and suppliers who submit claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9878 updates the Remittance Advice Remark Code (RARC) and Claim Adjustment Reason Code (CARC) lists. CR9878 also calls for an update to Medicare Remit Easy Print (MREP) and PC Print software. If you use MREP and/or PC Print software, be sure to obtain the latest version that is released on or before July 3, 2017. Make sure that your billing staffs are aware of these changes.

Background

The Health Insurance Portability and Accountability Act (HIPAA) of 1996 instructs health plans to be able to conduct standard electronic transactions adopted under HIPAA using valid standard codes. Medicare policy states that CARCs and RARCs, as appropriate, that provide either supplemental explanation for a monetary adjustment or policy information that generally applies to the monetary adjustment, are required in the remittance advice and coordination of benefits transactions.
The Centers for Medicare & Medicaid Services (CMS) instructs MACs to conduct updates based on the code update schedule that is published three times per year – around March 1, July 1, and November 1.

CR9878 provides notification indicating when updates to CARC and RARC lists are made available on the Washington Publishing Company (WPC) website. Medicare’s Shared System Maintainers (SSMs) have the responsibility to implement code deactivation, 1) making sure that any deactivated code is not used in original business messages, and 2) allowing the deactivated code in derivative messages. SSMs must make sure that Medicare does not report any deactivated code on or after the effective date for deactivation as posted on the WPC website. If any new or modified code has an effective date past the implementation date specified in CR9878, MACs must implement on the date specified on the WPC website.

A discrepancy between the dates may arise as the WPC website is only updated three times per year and may not match the CMS release schedule. For CR9878, MACs and SSMs must determine the changes that are included on the code list since the last code update CR (CR 9774) or its corresponding MM Article (MM9774).

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.
Updates to the “Medicare Claims Processing Manual,” Pub. 100-04, Chapters 12, 17 and 23 to Correct Remittance Advice Messages

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

What You Need to Know

This article is based on Change Request (CR) 9906, which revises Chapters 12, 17, and 23 of the “Medicare Claims Processing Manual” (the manual) to ensure that all remittance advice coding is consistent with national standard operating rules. It also provides a format for consistently showing remittance advice coding throughout this manual. MACs will ensure that they apply remittance advice coding as described in the revised manual sections. Make sure that your billing staffs are aware of these changes.

Background

Section 1171 of the Social Security Act requires a standard set of operating rules to regulate the health insurance industry’s use of Electronic Data Interchange (EDI) transactions. Operating Rule 360: Uniform Use of CARCs and RARCs, regulates the way in which group codes, Claims Adjustment Reason Codes (CARCs) and Remittance Advice Remark Codes (RARCs) may be used. The rule requires specific codes, which are to be used in combination with one another if one of the named business scenarios applies. This rule is authored by the Council for Affordable Quality Healthcare (CAQH) Committee on Operating Rules for Information Exchange (CORE).
MLN Matters® Number: MM9906 Related Change Request Number: 9906

Medicare and all other payers must comply with the CAQH CORE-developed code combinations. The business scenario for each payment adjustment must be defined, if applicable, and a valid code combination selected for all remittance advice messages. CR9906 updates Chapters 12, 17, and 23 of the manual to reflect the standard format and to correct any non-compliant code combinations.

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.
Provider Education

EDUCATION SCHEDULE

WPS GHA Learning Center

WPS GHA Provider Outreach and Education (POE) has transitioned to a new learning portal for your education needs. The WPS GHA Learning Center houses on-demand learning, information about live events, and the ability to receive Certificates of Achievement. These certificates may be submitted for consideration to earn Continuing Education Units (CEUs). For information on how to access, register as a user, and set up a profile for the Learning Center, go to our Learning Center at https://wpsgha.litmos.com/account/login/.

Event Schedule

WPS GHA offers a variety of education in a variety of formats throughout the year. To see our most current listing of seminars, teleconferences, and webinars please visit the WPS GHA Learning Center at: http://wpsgha.litmos.com/online-courses.

New offerings!

New to Medicare Teleconference Series

In-Person Events

A Day with Medicare
07/11/2017 — Salina, KS — 8:30 am – 4:30 pm CT
07/13/2017 — Des Moines, IA — 8:30 am – 4:30 pm CT

Don’t Miss This FREE Full Day Educational Opportunity!

This exciting program includes both Part A and Part B topics to gain insight into the cause for errors and how to avoid them in the future, including:

- General session
- 12 breakout sessions
- Question and answer session
- More!

Don't Get Wrapped Up in Overlapping Claims (Part B)
07/24/2017 — Traverse City, MI — 1:00 pm - 4:30 pm ET
07/26/2017 — Livonia, MI — 1:00 pm - 4:00 pm ET
08/15/2017 — Topeka, KS — 1:00 pm - 4:00 pm CT
10/18/2017 — St. Charles, MO — 1:00 pm - 4:00 pm CT

Some of the topics to be covered include:

- 3/1-day payment window
- End Stage Renal Disease (ESRD) Consolidated Billing
- Home Health Consolidated Billing
- What Place of Service (POS) Part B providers should use
• Steps you can take to resolve overlapping claim issues with another provider

Chiropractic

Medicare Coverage of Chiropractic Care
06/07/2017 — Lawrence, KS — 1:00 pm – 4:00 pm CT
08/30/2017 — Kentwood (Grand Rapids), MI — 1:00 pm – 4:00 pm ET

WPS GHA is pleased to offer a three-hour session designed specifically for those who wish to increase their knowledge of chiropractic care as it relates to Medicare.

Claims

Actions on Claims
08/17/2017 — Merrillville, IN — 8:30 am – 11:30 am CT
10/12/2017 — University Center, MI — 8:30 am – 11:30 am ET
10/26/2017 — Indianapolis, IN — 8:30 am – 11:30 am ET
11/16/2017 — Ankeny, Iowa — 8:30 am – 11:30 am CT

This course will answer those questions by covering the following:
• Action on claims that are not adjudicated
• Claim’s reopening process
• Claim’s appeal process
• Appeal dismissals and duplicate requests
• And more

CMS-1500 Billing Denials
08/16/2017 — Merrillville, IN — 8:30 am – 4:00 pm CT
10/11/2017 — University Center, MI — 8:30 am – 11:30 am ET
10/25/2017 — Indianapolis, IN — 8:30 am – 4:00 pm ET
11/15/2017 — Ankeny, IA — 8:30 am – 4:00 pm CT

We will cover how to fix and avoid the top claim denials.

Training topics
• Top claim denials
• Resources to help work with denials
• Top unprocessable errors
• Departmental denials
• And more

Focus On: Avoiding Medicare Secondary Payer (MSP) Denials
08/15/2017 — Merrillville, IN — 1:00 pm – 4:00 pm CT
10/10/2017 — University Center, MI — 1:00 pm – 4:00 pm ET
10/24/2017 — Indianapolis, IN — 1:00 pm – 4:00 pm ET
11/14/2017 — Ankeny, Iowa — 1:00 pm – 4:00 pm CT

Our agenda will include:
• Examine the most common MSP errors
• Understand what the denials mean
• Explore ways to correct and prevent them

Focus On: Claim Determinations from Other Contractors
08/17/2017 — Merrillville, IN — 1:00 pm – 4:00 pm CT
10/12/2017 — University Center, MI — 1:00 pm – 4:00 pm ET
10/26/2017 — Indianapolis, IN — 1:00 pm – 4:00 pm ET
11/16/2017 — Ankeny, Iowa — 1:00 pm – 4:00 pm CT

CMS employs a variety of contractors to process and review claims according to Medicare rules and regulations. In this session, we will examine some of the denials being assessed by these contractors, understand WPS GHA’s involvement in the process and explore ways to prevent the errors from happening in the future. The agenda will include:
• Discuss the role of other contractors
• View data showing reasons for denial
• Understand WPS GHA’s role

The World of a Claim
08/15/2017 — Merrillville, IN — 8:30 am – 11:30 am CT
10/10/2017 — University Center, MI — 8:30 am – 11:30 am ET
10/24/2017 — Indianapolis, IN — 8:30 am – 11:30 am ET
11/14/2017 — Ankeny, IA — 8:30 am – 11:30 am CT

The seminar covers:
• What information to get from the patient
• Determining who to bill
• A high-level documentation overview
• An overview of the process Medicare follows with the claim
• An overview of Skilled Nursing Facility Consolidated Billing

Consolidated Billing
An Interactive Day of Skilled Nursing Facility (SNF) Consolidated Billing
07/27/2017 - Livonia, MI - 8:30 am - 4:00 pm ET
08/16/2017 — Topeka, KS — 8:30 am - 4:00 pm CT
10/19/2017 — St. Charles, MO — 8:30 am - 4:00 pm CT

This will be an INTENSIVE day of hands-on training and implementing strategies that will give you the tools you need to be the subject matter expert in your office.

Documentation

Does Your Medicare Documentation Measure Up?
08/15/2017 — Merrillville, IN — 8:30 am – 4:00 pm CT
10/10/2017 — University Center, MI — 8:30 am – 4:00 pm ET
10/24/2017 — Indianapolis, IN — 8:30 am – 4:00 pm ET
11/14/2017 — Ankeny, IA — 8:30 am – 4:00 pm CT

Join WPS GHA for a live seminar in which we will
• Identify and discuss Medicare medical review contractors
• Identify Medicare documentation guidelines
• Discuss the dos’ and don’ts of Medicare documentation
• Review actual documentation that was considered in coverage determinations

**Medicare Part B Denials – Are Your Physicians Measuring Up?**
08/17/2017 — Merrillville, IN — 8:30 am – 4:00 pm CT
10/12/2017 — University Center, MI — 8:30 am – 4:00 pm ET
10/26/2017 — Indianapolis, IN — 8:30 am – 4:00 pm ET
11/16/2017 — Ankeny, IA – 8:30 am – 4:00 pm CT

In this live session, we will review the most common Part B claim review denials as well as practical documentation strategies to avoid documentation issues for your physician/office.

**Mental Health**

**Outpatient Mental Health – The Basics**
08/29/2017 — Kentwood (Grand Rapids), MI — 9:00 am – 12:00 pm ET

Participants in this seminar will hear an overview of the Medicare mental health benefit and increase their understanding of CMS national coverage policy and WPS GHA Local Coverage Determination (LCD) L34616, Psychiatry and Psychology Services.

**Part B Mental Health – Building on Basics**
08/29/2017 — Kentwood (Grand Rapids), MI — 1:00 pm – 4:00 pm ET

This program is designed for providers, coders, billers, office staff and compliance staff wishing to build on basic knowledge of Part B mental health services, including an opportunity to become more familiar with payment for psychiatry and psychological services under Medicare’s incident to provision.

Continue to watch the Wednesday eNews for the most current education topics available.

**Important Notice Regarding 2017 Seminar Materials**

In an effort to adopt consistent industry trends, beginning in 2017, WPS GHA will offer seminar materials only in an electronic format. Seminar registrants are responsible for printing and bringing their own handouts. To access, choose the Additional References tab in the Learning Center course.

**MEDI CARE LEARNI NG NETWORK (MLN)**

We encourage you to visit the Medicare Learning Network the place for official CMS Medicare fee-for-service provider educational information. There you can find one of our most popular products, MLN Matters national provider education articles. These articles help you understand new or changed Medicare policy and how those changes affect you. A full array of other educational products (including Web-based training courses, hard copy and downloadable publications, and CD-ROMs) are also available and can be accessed at: [http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/index.html](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/index.html). You can also find other important Web sites by visiting the Physician Center Web page at: [http://www.cms.gov/Center/Provider-Type/Physician-](http://www.cms.gov/Center/Provider-Type/Physician-)
In addition to educational products, the MLN also offers providers and suppliers opportunities to learn more about the Medicare program through MLN National Provider Calls. These national conference calls, held by CMS for the Medicare Fee-For-Service provider and supplier community, educate and inform participants about new policies and/or changes to the Medicare program. Offered free of charge, continuing education credits may be awarded for participation in certain National Provider Calls. To learn more about MLN National Provider Calls including upcoming calls, registration information, and links to previous call materials, visit http://www.cms.gov/Outreach-and-Education/Outreach/NPC/index.html.

QUARTERLY PROVIDER UPDATE

The Quarterly Provider Update is a comprehensive resource published by the Centers for Medicare & Medicaid Services (CMS) on the first business day of each quarter. It is intended to make it easier for providers, suppliers, and the general public to understand the changes CMS is proposing or making.

CMS publishes this update to inform the public about the following:

- Regulations and major policies currently under development during this quarter.
- Regulations and major policies completed or cancelled.
- New/Revised manual instructions


We encourage you to bookmark this web page and visit it often for this valuable information. To receive notification when regulations and program instructions are added throughout the quarter, sign up for the Quarterly Provider Update Listserv at: https://public.govdelivery.com/accounts/USCMS/subscriber/new?topic_id=USCMS_460.
Reimbursement

**UNSOLICITED/VOLUNTARY REFUNDS**

The acceptance of a voluntary refund as repayment for the claims specified in no way affects or limits the rights of the Federal Government, or any of its agencies or agents, to pursue any appropriate criminal, civil, or administrative remedies arising from or relating to these or any other claims.

Please see [MLN Matters Article (MM) 3274](http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM3274.pdf) for more information.
**April 2017 Update of the Ambulatory Surgical Center (ASC) Payment System**

**Provider Types Affected**

This MLN Matters® Article is intended for physicians, other providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for Ambulatory Surgical Center (ASC) services to Medicare beneficiaries.

**Provider Action Needed**

Change Request (CR) 9998, from which this article was developed, describes changes to and billing instructions for various payment policies implemented in the April 2017 ASC payment system update. This Recurring Update Notification applies to Chapter 14, Section 10 of the Medicare Claims Processing Manual (Pub. 100-04), available at [https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c14.pdf](https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c14.pdf) on the Centers for Medicare & Medicaid Services (CMS) website. As appropriate, this notification also includes updates to the Healthcare Common Procedure Coding System (HCPCS).

**Background**

Included in this CR are updates to payment rates for separately payable drugs and biologicals, including descriptors for newly created Level II HCPCS codes for drugs and biologicals (ASC DRUG files). There is no ASC Fee Schedule (ASCFS) being issued this quarter.

---

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.
Drugs, Biologicals, and Radiopharmaceuticals

ASC Drugs and Biologicals with OPPS Pass-Through Status Effective April 1, 2017

For Calendar Year 2017, several new HCPCS codes, with OPPS Pass-Through Status, have been created for reporting drugs and biologicals in the ASC payment system, where there have not previously been specific codes available. These new codes are in Table 1.

Table 1: ASC Drugs and Biologicals with OPPS Pass-Through Status Effective April 1, 2017

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long Descriptor</th>
<th>Short Descriptor</th>
<th>ASC PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9484</td>
<td>Injection, eteplirsen, 10 mg</td>
<td>Injection, eteplirsen</td>
<td>K2</td>
</tr>
<tr>
<td>C9485</td>
<td>Injection, olaratumab, 10 mg</td>
<td>Injection, olaratumab</td>
<td>K2</td>
</tr>
<tr>
<td>C9486</td>
<td>Injection, granisetron extended release, 0.1 mg</td>
<td>Inj, granisetron ext</td>
<td>K2</td>
</tr>
<tr>
<td>C9487</td>
<td>Ustekinumab, for intravenous injection, 1 mg</td>
<td>Ustekinumab IV inj, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9488</td>
<td>Injection, conivaptan hydrochloride, 1 mg</td>
<td>Conivaptan HCL</td>
<td>K2</td>
</tr>
<tr>
<td>J7328</td>
<td>Hyaluronan or derivative, gel-syn, for intra-articular injection, 0.1 mg</td>
<td>Gel-syn injection 0.1 mg</td>
<td>K2</td>
</tr>
</tbody>
</table>

Drugs and Biologicals with Payments Based on Average Sales Price (ASP) Effective April 1, 2017

For CY 2017, payment for nonpass-through drugs, biologicals, and therapeutic radiopharmaceuticals continues to be made at a single rate of ASP + 6 percent, which provides payment for both the acquisition cost and pharmacy overhead costs associated with the drug, biological, or therapeutic radiopharmaceutical. In addition, in CY 2017, a single payment of ASP + 6 percent continues to be made for pass-through drugs, biologicals, and radiopharmaceuticals is made to provide payment for both the acquisition cost and pharmacy overhead costs of these pass-through items.

Payments for drugs and biologicals based on ASPs will be updated on a quarterly basis as later-quarter ASP submissions become available. Updated payment rates effective April 1, 2017, and drug price restatements can be found at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/11_Addenda_Updates.html on the CMS website.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2015 American Medical Association. All rights reserved.
Drugs and Biologicals Based on ASP Methodology with Restated Payment Rates

Some drugs and biologicals based on ASP methodology may have payment rates that are corrected retroactively. These retroactive corrections typically occur on a quarterly basis. The list of drugs and biologicals with corrected payments will be accessible on the first date of the quarter at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/index.html on the CMS website.

Suppliers who think they may have received an incorrect payment for drugs and biologicals impacted by these corrections may request contractor adjustment of the previously processed claims.

Revised Payment Indicator for HCPCS Code J1130 Effective January 1, 2017

The status indicator for HCPCS Code J1130 (Injection, diclofenac sodium, 0.5 mg) will change from ASC PI=Y5 (Nonsurgical procedure/item not valid for Medicare purposes because of coverage, regulation and/or statute; no payment made) to ASC PI=K2 (Drugs and biological paid separately when provided integral to a surgical procedure on ASC list) in the April 2017 update. This status indicator correction will be retroactive to January 1, 2017. The correction is shown in Table 2.

Table 2: Revised Payment Indicator for HCPCS Code J1130 Effective January 1, 2017

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long Descriptor</th>
<th>Short Descriptor</th>
<th>ASC PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>J1130</td>
<td>Injection, diclofenac sodium, 0.5 mg</td>
<td>Inj diclofenac sodium 0.5mg</td>
<td>K2</td>
</tr>
</tbody>
</table>

HCPCS Code C9744

As a reminder to ASCs, HCPCS Code C9744 (Ultrasound, abdominal, with contrast) may be used to describe use of a contrast agent in ultrasonography of the liver, kidneys, and/or bladder.

Reassignment of Skin Substitute Product from the Low-Cost Group to the High-Cost Group

Four skin substitute products have been reassigned from the low-cost skin substitute group to the high-cost skin substitute group based on updated pricing information. The HCPCS codes are Q4161, Q4169, Q4173, and Q4175. ASCs should not separately bill for packaged skin substitutes (ASC PI=N1). These products are shown in Table 3.
Table 3: Reassignment of Skin Substitute Product from the Low-Cost Group to the High-Cost Group Effective April 1, 2017

<table>
<thead>
<tr>
<th>CY 2017 HCPCS Code</th>
<th>CY 2017 Short Descriptor</th>
<th>ASC PI</th>
<th>Low/High Cost Skin Substitute</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4161</td>
<td>Bio-Connekt per square cm</td>
<td>N1</td>
<td>High</td>
</tr>
<tr>
<td>Q4169</td>
<td>Artacent wound, per square cm</td>
<td>N1</td>
<td>High</td>
</tr>
<tr>
<td>Q4173</td>
<td>Palingen or palingen xplus, per sq cm</td>
<td>N1</td>
<td>High</td>
</tr>
<tr>
<td>Q4175</td>
<td>Miroderm, per square cm</td>
<td>N1</td>
<td>High</td>
</tr>
</tbody>
</table>

Removal of Skin Substitute Product from the High/Low-Cost Skin Substitute Table

HCPCS Code Q4171 was inadvertently included in the High/Low-Cost Skin Substitute table. Effective April 2017, Q4171 is removed from the High/Low-Cost Skin Substitute table. As a reminder, ASCs should not separately bill for packaged skin substitutes (ASC PI=N1). This product is listed in Table 4.

Table 4: Skin Substitute Product Removed from High/Low-Cost Skin Substitute Table Effective April 1, 2017

<table>
<thead>
<tr>
<th>CY 2017 HCPCS Code</th>
<th>CY 2017 Short Descriptor</th>
<th>ASC PI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4171</td>
<td>Interfyl, 1 mg</td>
<td>N1</td>
</tr>
</tbody>
</table>

Coverage Determinations: The fact that a drug, device, procedure, or service is assigned an HCPCS code and a payment rate under the ASC payment system does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. MACs determine whether a drug, device, procedure, or other service meets all program requirements for coverage. For example, MACs determine that it is reasonable and necessary to treat the beneficiary’s condition and whether it is excluded from payment.
Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/ on the CMS website.

Document History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 6, 2017</td>
<td>Article release</td>
</tr>
</tbody>
</table>
April Quarterly Update for 2017 Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Fee Schedule

Provider Types Affected

This MLN Matters® Article is intended for providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) items or services paid under the DMEPOS fee schedule.

What You Need to Know

Change Request (CR) 9988 provides the April 2017 quarterly update for the Medicare DMEPOS fee schedule, and it includes information, when necessary, to implement fee schedule amounts for new codes and correct any fee schedule amounts for existing codes.

Background

The DMEPOS fee schedules are updated on a quarterly basis, when necessary, in order to implement fee schedule amounts for new and existing codes, as applicable, and apply changes in payment policies. The quarterly update process for the DMEPOS fee schedule is located in the “Medicare Claims Processing Manual” (Pub.100-04, Chapter 23, Section 60).

Payment on a fee schedule basis is required for durable medical equipment (DME), prosthetic devices, orthotics, prosthetics, and surgical dressings by the Social Security Act (§1834(a), (h), and (i)). Also, payment on a fee schedule basis is a regulatory requirement at 42 Code of Federal Regulations (CFR) §414.102 for parenteral and enteral nutrition (PEN), splints and casts, and intraocular lenses (IOLs) inserted in a physician's office.

Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Additionally, Section §1834(a)(1)(F)(ii) of the Act mandates adjustments to the fee schedule amounts for certain items furnished on or after January 1, 2016, in areas that are not competitive bid areas, based on information from competitive bidding programs (CBPs) for DME. The Social Security Act (§1842(s)(3)(B)) provides authority for making adjustments to the fee schedule amount for enteral nutrients, equipment, and supplies (enteral nutrition) based on information from CBPs. Also, the adjusted fees apply a rural payment rule. The DMEPOS and PEN fee schedule files contain HCPCS codes that are subject to the adjustments as well as codes that are not subject to the fee schedule adjustments. Additional information on adjustments to the fee schedule amounts based on information from CBPs is available in CR 9642 (Transmittal 3551, dated June 23, 2016).

The ZIP code associated with the address used for pricing a DMEPOS claim determines the rural fee schedule payment applicability for codes with rural and non-rural adjusted fee schedule amounts. ZIP codes for non-continental Metropolitan Statistical Areas (MSA) are not included in the DMEPOS Rural ZIP code file. The DMEPOS Rural ZIP code file is updated on a quarterly basis as necessary.

The Calendar Year (CY) 2017 DMEPOS and PEN fee schedules and the April 2017 DMEPOS Rural ZIP code file public use files (PUFs) will be available for State Medicaid Agencies, managed care organizations, and other interested parties shortly after the release of the data files at [http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched](http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched).

**KU Modifier for Complex Rehabilitative Power Wheelchair Accessories & Seat and Back Cushions**

Section 16005 of the 21st Century Cures Act extends the effective date through June 30, 2017, to exclude adjustments to fees using information from CBPs for certain wheelchair accessories (including seating systems) and seat and back cushions furnished in connection with Group 3 complex rehabilitative power wheelchairs (codes K0848 through K0864). As a result, the KU modifier fees have been added back to the DMEPOS fee schedule file effective January 1, 2017, and are effective for dates of service through June 30, 2017. The fees for items denoted with the HCPCS modifier ‘KU’ represent the unadjusted fee schedule amounts (the CY 2015 fee schedule amount updated by the 2016 and 2017 DMEPOS covered item update factor of 0.7 percent). The applicable complex rehabilitative wheelchair accessory codes are listed in CR 9520 (Transmittal 3535, dated June 7, 2016).

**Note for Change Request 8822 Reclassification of Certain DME to the Capped Rental Payment Category**

For dates of service on or after January 1, 2017, payment for the following HCPCS codes in all geographic areas is made on a capped rental basis: E0197, E0140, E0149, E0985, E1020, E1028, E2228, E2368, E2369, E2370, E2375, K0015, K0070, and E0955.
For dates of service on or after July 1, 2016, through December 31, 2016, these HCPCS codes were reclassified from the payment category for inexpensive and routinely purchased DME to payment on a capped rental basis in all areas except the nine Round 1 Recompete (Round 1 2014) Competitive Bidding Areas (CBAs). Program instructions on these changes were issued in CR 8822 (Transmittal 1626, dated February 19, 2016) and CR 8566 (Transmittal 1332, dated January 2, 2014). Related MLN Matters articles are at https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM8822.pdf and https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM8566.pdf, respectively.

When submitting claims, suppliers that submit claims with more than four modifiers including when the claim is being billed with both the RT (right) and the LT (left) modifiers will include the NU (Purchase of new equipment) or RR (Rental) modifier as appropriate, the RT and LT modifiers and then the 99 modifier to signify that there are additional modifiers in use. On the narrative line, the supplier will include all applicable modifiers including the NU or RR, RT and LT modifiers.

**Example**

- Procedure code: E2370
- Units of Service = 2
- Modifiers: RR, LT, RT, 99 (RB, KX reported in additional narrative)

**Payment for Oxygen Volume Adjustments and Portable Oxygen Equipment**

CR 9848 (Transmittal 3679, dated December 16, 2016) titled Payment for Oxygen Volume Adjustments and Portable Oxygen Equipment, updated the “Medicare Claims Processing Manual” (Pub.100-04, chapter 20, section 130.6) to clarify billing when the prescribed amount of stationary oxygen exceeds 4 liters per minute (LPM) and portable oxygen is prescribed. The QF modifier is used to denote when the oxygen flow exceeds 4 LPM and portable oxygen is prescribed.

The Social Security Act (§ 1834(a)(5)(C) and (D)) requires that when there is an oxygen flow rate that exceeds 4 LPM that the Medicare payment amount be the higher of 50 percent of the stationary payment amount (codes E0424, E0439, E1390, or E1392) or the portable oxygen add-on amount (E0431, E0433, E0434, E1392, or K0738), and never both.

To facilitate this payment calculation, the QF modifier is added to the DMEPOS fee schedule file effective April 1, 2017, for both stationary and portable oxygen. The stationary oxygen QF modifier fee schedule amounts represent 100 percent of the stationary oxygen fee schedule amount. The portable oxygen QF fee schedule amounts represent the higher of 50 percent of the monthly stationary oxygen payment amount or the fee schedule amount for the portable oxygen add-on amount.

Disclaimer
This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Effective April 1, 2017, the modifier “QF” should be used in conjunction with claims submitted for stationary oxygen (codes E0424, E0439, E1390, or E1391) and portable oxygen (codes E0431, E0433, E0434, E1392, or K0738) when the prescribed amount of oxygen is greater than 4 liters per minute (LPM).

Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

Document History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 6, 2017</td>
<td>Article released</td>
</tr>
</tbody>
</table>
Clinical Laboratory Fee Schedule – Medicare Travel Allowance Fees for Collection of Specimens

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

Provider Action Needed

Change Request (CR) 9960 revises the payment of travel allowances when billed on a per mileage basis using Health Care Common Procedure Coding System (HCPCS) code P9603 and when billed on a flat-rate basis using HCPCS code P9604 for Calendar Year (CY) 2017. Make sure that your billing staffs are aware of these changes.

Background

Medicare Part B allows payment for a specimen collection fee and travel allowance, when medically necessary, for a laboratory technician to draw a specimen from either a nursing home patient or homebound patient under Section 1833(h)(3) of the Act. Payment for these services is made based on the clinical laboratory fee schedule.

Key Changes

The travel codes allow for payment either on a per mileage basis (P9603) or on a flat-rate per trip basis (P9604). Payment of the travel allowance is made only if a specimen collection fee is also payable. The travel allowance is intended to cover the estimated travel
costs of collecting a specimen including the laboratory technician’s salary and travel expenses. MAC discretion allows the contractor to choose either a mileage basis or a flat rate, and how to set each type of allowance. Because audits have shown that some laboratories abused the per mileage fee basis by claiming travel mileage in excess of the minimum distance necessary for a laboratory technician to travel for specimen collection, many MACs established local policy to pay based on a flat-rate basis only.

Under either method, when one trip is made for multiple specimen collections (for example, at a nursing home), the travel payment component is prorated based on the number of specimens collected on that trip. This applies to both Medicare and non-Medicare patients, either at the time the claim is submitted by the laboratory or when the flat rate is set by the MAC.

- **Per Mile Travel Allowance (P9603)** - The per mile travel allowance is to be used in situations where the average trip to the patients’ homes is longer than 20 miles round trip, and is to be prorated in situations where specimens are drawn from non-Medicare patients in the same trip.

  The allowance per mile was computed using the Federal mileage rate of $0.535 per mile plus an additional $0.45 per mile to cover the technician’s time and travel costs. MACs have the option of establishing a higher per mile rate in excess of the minimum $0.99 per mile ($0.985 is rounded up for system purposes) if local conditions warrant it. The minimum mileage rate will be reviewed and updated throughout the year, as well as in conjunction with the Clinical Laboratory Fee Schedule (CLFS), as needed. At no time will the laboratory be allowed to bill for more miles than are reasonable, or for miles that are not actually traveled by the laboratory technician.

- **Per Flat-Rate Trip Basis Travel Allowance (P9604)** - The per flat-rate trip basis travel allowance is $9.85.

The Internal Revenue Service (IRS) determines the standard mileage rate for businesses based on periodic studies of the fixed and variable costs of operating an automobile.

**Additional Information**


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
MLN Matters® Number: MM9916 Rescinded Related Change Request (CR) #: CR 9916
Related CR Release Date: February 17, 2017 Effective Date: July 1, 2017
Related CR Transmittal #: R169DEMO Implementation Date: July 3, 2017

Episode Payment Model Operations

Note: This article has been rescinded as CR9916 was rescinded. The CR will be replaced at a later date.
July 2017 Quarterly Average Sales Price (ASP)
Medicare Part B Drug Pricing Files and Revision to
Prior Quarterly Pricing Files

MLN Matters Number: MM10016  Related Change Request (CR) Number: 10016
Related CR Release Date: April 7, 2017  Effective Date: July 1, 2017
Related CR Transmittal Number: R3746CP  Implementation Date: July 3, 2017

PROVIDER TYPE AFFECTED

This MLN Matters® Article is intended for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

Change Request (CR) 10016 provides the July 2017 quarterly update and instructs MACs to download and implement the July 2017 ASP drug pricing files and, if released by the Centers for Medicare & Medicaid Services (CMS), the revised April 2017, January 2017, October 2016, and July 2016 Average Sales Price (ASP) drug pricing files for Medicare Part B drugs. Medicare will use these files to determine the payment limit for claims for separately payable Medicare Part B drugs processed or reprocessed on or after July 3, 2017, with dates of service July 1, 2017, through September 30, 2017. MACs will not search and adjust claims previously processed unless brought to their attention.

BACKGROUND

The ASP methodology is based on quarterly data submitted to CMS by manufacturers. CMS will supply contractors with the ASP and Not Otherwise Classified (NOC) drug-pricing files for Medicare Part B drugs on a quarterly basis. Payment allowance limits under the OPPS are incorporated into the Outpatient Code Editor (OCE) through separate instructions. The following files are related to this most recent update:

- July 2017 ASP and ASP NOC – Effective Dates of Service: July 1, 2017, through September 30, 2017
April 2017 ASP and ASP NOC – Effective Dates of Service: April 1, 2017, through June 30, 2017

January 2017 ASP and ASP NOC – Effective Dates of Service: January 1, 2017, through March 31, 2017

October 2016 ASP and ASP NOC – Effective Dates of Services: October 1, 2016, through December 31, 2016

July 2016 ASP and ASP NOC – Effective Dates of Service: July 1, 2016, through September 30, 2016

For any drug or biological not listed in the ASP or NOC drug-pricing files, MACs will determine the payment allowance limits in accordance with the policy described in the “Medicare Claims Processing Manual,” Chapter 17, Section 20.1.3, which is available at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c17.pdf. For any drug or biological not listed in the ASP or NOC drug-pricing files that is billed with the KD modifier, contractors shall determine the payment allowance limits in accordance with instructions for pricing and payment changes for infusion drugs furnished through an item of Durable Medical Equipment (DME) on or after January 1, 2017, associated with the passage of the 21st Century Cures Act.

ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/ Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 7, 2017</td>
<td>Initial Article Released</td>
</tr>
</tbody>
</table>

Disclaimer This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
July Quarterly Update for 2017 Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Fee Schedule

MLN Matters Number: MM10071  Related Change Request (CR) # 10071
Related CR Release Date: April 28, 2017  Effective Date: July 1, 2017
Related CR Transmittal Number: R3760CP  Implementation Date: July 3, 2017

PROVIDER TYPE AFFECTED

This MLN Matters® Article is intended for providers and suppliers submitting claims to Medicare Administrative Contractors (MACs) for Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) items or services paid under the DMEPOS fee schedule.

PROVIDER ACTION NEEDED

Change Request (CR) 10071 provides the July 2017 quarterly update for the Medicare DMEPOS fee schedule, and it includes information, when necessary, to implement fee schedule amounts for new codes and correct any fee schedule amounts for existing codes.

BACKGROUND

The DMEPOS fee schedules are updated on a quarterly basis, when necessary, in order to implement fee schedule amounts for new and existing codes, as applicable, and apply changes in payment policies. The quarterly update process for the DMEPOS fee schedule is located in the Medicare Claims Processing Manual, Chapter 23, Section 60 at https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c23.pdf.


Also, payment on a fee schedule basis is a regulatory requirement at 42 Code of Federal Regulations (CFR) §414.102, for parenteral and enteral nutrition (PEN), splints and casts and intraocular lenses (IOLs) inserted in a physician’s office.

Additionally, Section 1834 of the Act mandates adjustments to the fee schedule amounts for
certain items furnished on or after January 1, 2016, in areas that are not competitive bid areas (CBAs), based on information from competitive bidding programs (CBPs) for DME. The Social Security Act (§1842(s)(3)(B)) provides authority for making adjustments to the fee schedule amount for enteral nutrients, equipment and supplies (enteral nutrition) based on information from CBPs. Also, the adjusted fees apply a rural payment rule. The DMEPOS and PEN fee schedule files contain HCPCS codes that are subject to the adjustments as well as codes that are not subject to the fee schedule adjustments. Additional information on adjustments to the fee schedule amounts based on information from CBPs is available in CR 9642 (Transmittal 3551, dated June 23, 2016).

The ZIP code associated with the address used for pricing a DMEPOS claim determines the rural fee schedule payment applicability for codes with rural and non-rural adjusted fee schedule amounts. ZIP codes for non-continental Metropolitan Statistical Areas (MSA) are not included in the DMEPOS Rural ZIP code file. The DMEPOS Rural ZIP code file is updated on a quarterly basis as necessary.

The Calendar Year (CY) 2017 DMEPOS and PEN fee schedules and the July 2017 DMEPOS Rural ZIP code file public use files (PUFs) will be available for State Medicaid Agencies, managed care organizations, and other interested parties shortly after the release of the data files at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/DMEPOSFeeSched.

KU Modifier for Complex Rehabilitative Power Wheelchair Accessories & Seat and Back Cushions

Effective July 1, 2017, the fee schedule amounts for wheelchair accessories and seat and back cushions denoted with the HCPCS modifier ‘KU’ are deleted from the DMEPOS fee schedule file. These unadjusted fee schedule amounts have applied to wheelchair accessories and seat and back cushions furnished in connection with Group 3 complex rehabilitative power wheelchairs (codes K0848 through K0864). The fee schedule amounts associated with the KU modifier were mandated by Section 2 of Patient Access and Medicare Protection Act (PAMPA) effective for dates of service January 1, 2016 through December 31, 2016. Additionally, section 16005 of the 21st Century Cures Act extended the effective date through June 30, 2017. The list of HCPCS codes to which this statutory section applied is available in Transmittal 3535, CR 9520 dated June 7, 2016.

Therapeutic Continuous Glucose Monitor (CGM)

As part of this update, the fee schedule amounts for the following therapeutic CGM HCPCS codes are added to the DMEPOS fee schedule file effective for dates of service on or after July 1, 2017:

- K0553 - Supply allowance for therapeutic continuous glucose monitor (CGM), includes all supplies and accessories, 1 unit of service = 1 month's supply
- K0554 - Receiver (monitor), dedicated, for use with therapeutic continuous glucose monitor system

ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 2, 2017</td>
<td>Initial Article Released</td>
</tr>
</tbody>
</table>

Disclaimer  This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Payment for Moderate Sedation Services

Provider Types Affected

This MLN Matters® Article is intended for physicians and other providers submitting claims to Medicare Administrative Contractors (MACs) for moderate sedation and anesthesia services provided to Medicare beneficiaries.

What You Need to Know

Change Request (CR) 10001 revises existing Medicare Claims Processing Manual language to bring the manual in line with current payment policy for moderate sedation and anesthesia services. Providers should refer to the revised Medicare Claims Processing Manual, Chapter 12 (Physicians/Nonphysician Practitioners), Sections 50 and 140 for information regarding the reporting of moderate sedation and anesthesia services. The revision is attached to CR10001. Make sure your billing staff is aware of these revisions.

Key Manual Changes

General Payment Rule

The fee schedule amount for physician anesthesia services furnished is, with the exceptions noted, based on allowable base and time units multiplied by an anesthesia conversion factor specific to that locality. The base unit for each anesthesia procedure is communicated to the MACs by means of the Healthcare Common Procedure Coding System (HCPCS) file released annually. The Centers for Medicare & Medicaid Services (CMS) releases the conversion factor annually. The base units and conversion factor are available at https://www.cms.gov/Center/Provider-Type/Anesthesiologists-Center.html.
Moderate Sedation Services Furnished in Conjunction with and in Support of Procedural Services

Anesthesia services range in complexity. The continuum of anesthesia services, from least intense to most intense in complexity is as follows: local or topical anesthesia, moderate (conscious) sedation, regional anesthesia and general anesthesia. Moderate sedation is a drug induced depression of consciousness during which the patient responds purposefully to verbal commands, either alone or accompanied by light tactile stimulation. Moderate sedation does not include minimal sedation, deep sedation or monitored anesthesia care.

Practitioners will report the appropriate CPT and/or HCPCS code that accurately describes the moderate sedation services performed during a patient encounter, which are performed in conjunction with and in support of a procedural service, consistent with CPT guidance.

Other Manual Revisions to Sections 50 and 140
There are other minor revisions to these manual sections and those revised manual sections are attached to CR10001.

Additional Information

Your MAC will not search their files to either retract payment for claims already paid or to retroactively pay claims. They will adjust impacted claims that you bring to their attention.


If you have any questions, please contact your MAC at their toll-free number. That number is available at https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/.

Document History

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>04-14-2017</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>
Payment for Moderate Sedation Services Furnished with Colorectal Cancer Screening Tests

MLN Matters Number: MM10075 Related Change Request (CR) Number: 10075
Related CR Release Date: April 28, 2017 Effective Date: January 1, 2017
Related CR Transmittal Number: R3763CP Implementation Date: October 2, 2017

PROVIDER TYPE AFFECTED

This MLN Matters article is intended for physicians and other providers submitting claims to Part A and B Medicare Administrative Contractors (MACs) for sedation services furnished with colorectal cancer screening tests.

PROVIDER ACTION NEEDED

Change Request (CR) 10075 ensures accurate program payment for moderate sedation services furnished in conjunction with screening colonoscopy services for which the beneficiary should not be charged the coinsurance or deductible. The coinsurance and deductible for these services are waived, but due to coding changes and additions to the Medicare Physician Fee Schedule (MPFS) Database the payments for Calendar Year (CY) 2017 would not be accurate without this CR. Please make your billing staff aware of these changes.

BACKGROUND

Section 4104 of the Affordable Care Act defined the term “preventive services” to include “colorectal cancer screening tests” and, as a result, it waives any coinsurance that would otherwise apply under Section 1833(a)(1) of the Social Security Act for screening colonoscopies. In addition, the ACA amended Section 1833(b)(1) of the Act to waive the Part B deductible for screening colonoscopies, which includes moderate sedation services as an inherent part of the screening colonoscopy procedural service. These provisions are effective for services furnished on or after January 1, 2011.

In the CY 2017 PFS Final Rule, the Centers for Medicare & Medicaid Services (CMS) modified coding and reporting of procedural services that include moderate sedation as an inherent part of the service, including for screening colonoscopies. CR 10075 operationalizes the existing waiver of deductible and coinsurance for moderate sedation services furnished in conjunction with and in support of colorectal cancer screening tests. Effective January 1, 2017, beneficiary
coinsurance and deductible continues to not apply to the following moderate sedation claim lines when furnished in conjunction with screening colonoscopy services and when billed with Modifier 33 or Modifier PT:

- **HCPCS code G0500**: Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient’s level of consciousness and physiological status; patient age 5 years or older (additional time may be reported with 99153, as appropriate).

- **CPT code 99153**: Moderate sedation services provided by the same physician or other qualified healthcare professional performing the diagnostic or therapeutic service that the sedation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient’s level of consciousness and physiological status; each additional 15 minutes of intra-service time (List separately in addition to code for primary service).

MACS will not search their files to either retract payment for claim lines already paid or to retroactively pay claim lines with HCPCS code G0500 or CPT code 99153. However, MACs will adjust such claims that you bring to their attention.

### ADDITIONAL INFORMATION


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

### DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 1, 2017</td>
<td>Initial article released</td>
</tr>
</tbody>
</table>

**Disclaimer** This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
Quarterly Update to the Medicare Physician Fee Schedule Database (MPFSDB) - April CY 2017 Update

Provider Types Affected

This MLN Matters® Article is intended for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries and subject to the Medicare Physician Fee Schedule (MPFS).

Provider Action Needed

Change Request (CR) 9977 informs MACs about changes to the MPFS payment files. While the changes will be implemented in Medicare systems on April 3, the changes are effective January 1, 2017. Note that MACs need not search their files to either retract payment for claims already paid or to retroactively pay claims already processed. However, the MACs will adjust such claims that you bring to their attention. Make sure that your billing staffs are aware of these changes.

Background

Payment files were issued to the MACs based upon the CY 2017 MPFS Final Rule, published in the Federal Register on November 15, 2016, to be effective for services furnished between January 1, 2017, and December 31, 2017.
Below is a summary of the changes for the April update to the 2017 MPFSDB. These changes are effective for dates of service on or after January 1, 2017.

<table>
<thead>
<tr>
<th>CPT/HCPCS Code</th>
<th>MOD</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>G0477</td>
<td></td>
<td>Procedure Status = I</td>
</tr>
<tr>
<td>G0478</td>
<td></td>
<td>Procedure Status = I</td>
</tr>
<tr>
<td>G0479</td>
<td></td>
<td>Procedure Status = I</td>
</tr>
<tr>
<td>22867</td>
<td></td>
<td>Assistant Surgery Indicator = 2</td>
</tr>
<tr>
<td>22869</td>
<td></td>
<td>Assistant Surgery Indicator = 2</td>
</tr>
<tr>
<td>76519</td>
<td>26</td>
<td>Bilateral Surgery Indicator = 3</td>
</tr>
<tr>
<td>92136</td>
<td>26</td>
<td>Bilateral Surgery Indicator = 3</td>
</tr>
<tr>
<td>97161</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.00</td>
</tr>
<tr>
<td>97162</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.00</td>
</tr>
<tr>
<td>97163</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.00</td>
</tr>
<tr>
<td>97165</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.32</td>
</tr>
<tr>
<td>97166</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.32</td>
</tr>
<tr>
<td>97167</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 1.32</td>
</tr>
<tr>
<td>97168</td>
<td></td>
<td>Non-facility &amp; Facility PE RVU = 0.93</td>
</tr>
</tbody>
</table>

In addition, the following new codes have been added to the HCPCS file effective February 1, 2017. The HCPCS file coverage code is C (carrier judgment) for these new codes. Coverage and payment will be determined by the MAC (they are not part of the MPFS).

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Short Descriptor</th>
<th>Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>0001U</td>
<td>RBC DNA HEA 35 AG 11 BLD GRP</td>
<td>Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported</td>
</tr>
<tr>
<td>0002U</td>
<td>ONC CLRCT 3 UR METAB ALG PLP</td>
<td>Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps</td>
</tr>
</tbody>
</table>
### CPT Code

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Short Descriptor</th>
<th>Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>0003U</td>
<td>ONC OVAR 5 PRTN</td>
<td>Oncology (ovarian) biochemical assays of five proteins</td>
</tr>
<tr>
<td></td>
<td>SER ALG SCOR</td>
<td>(apolipoprotein A-1, CA 125 II, follicle stimulating hormone,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>human epididymis protein 4, transferrin), utilizing serum,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>algorithm reported as a likelihood score</td>
</tr>
</tbody>
</table>

### Additional Information


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/).

### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.
WPS GHA PROVIDER SERVICES

For additional information on the content of this newsletter, changes in policy or procedures, how to obtain a hardcopy of a Local Coverage Determination (LCD), or if you experience difficulties obtaining a policy on our website, please contact a customer service representative at the telephone numbers/addresses listed below.

<table>
<thead>
<tr>
<th>J5 MAC PART B (IA, KS, MO, NE)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Iowa</td>
<td>Kansas</td>
</tr>
<tr>
<td>WPS GHA General Correspondence</td>
<td>WPS GHA General Correspondence</td>
</tr>
<tr>
<td>P.O. Box 8550</td>
<td>P.O. Box 7238</td>
</tr>
<tr>
<td>Madison, WI 53708-8550</td>
<td>Madison, WI 53707-7238</td>
</tr>
<tr>
<td>(866) 518-3285</td>
<td>(866) 518-3285</td>
</tr>
<tr>
<td>Missouri</td>
<td>Nebraska</td>
</tr>
<tr>
<td>WPS GHA General Correspondence</td>
<td>WPS GHA General Correspondence</td>
</tr>
<tr>
<td>P.O. Box 14260</td>
<td>P.O. Box 8667</td>
</tr>
<tr>
<td>Madison, WI 53708-0260</td>
<td>Madison, WI 53708-8667</td>
</tr>
<tr>
<td>(866) 518-3285</td>
<td>(866) 518-3285</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>J8 MAC PART B (IN, MI)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Indiana</td>
<td>Michigan</td>
</tr>
<tr>
<td>WPS GHA General Correspondence</td>
<td>WPS GHA General Correspondence</td>
</tr>
<tr>
<td>P.O. Box 8580</td>
<td>P.O. Box 8939</td>
</tr>
<tr>
<td>Madison, WI 53708-8580</td>
<td>Madison, WI 53708-8939</td>
</tr>
<tr>
<td>(866) 234-7331</td>
<td>(866) 234-7331</td>
</tr>
</tbody>
</table>

VISIT WPSGHA.COM FOR ALL YOUR MEDICARE NEEDS

WPS GHA would like to remind providers that the Communiqué does not include all the information needed by Medicare providers. While the publication does include general information, articles, and updates, the most comprehensive source of WPS GHA information is the WPS GHA website (http://www.wpsgHA.com/). Visit us today!

WPS GHA MEDICARE eNEWS MESSAGES

Stay up-to-date on Medicare issues by signing up for our free WPS GHA Medicare eNews. By subscribing, you can enjoy a free, easy, and secure way to stay current on the latest Medicare information, with the option to unsubscribe at any time. To receive our eNews messages, go to https://corp-ws.wpsic.com/apps/commercial/unauth/medicareListservUserWelcomeLoadAction.do. Follow the site’s instructions for signing up and simply check your email regularly to receive the latest Medicare information.